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SUMMARY 
Cholesterol is an essential component of membranes in higher eukaryotes, and a precursor 
for further important sterols. Abnormally high or low levels of cholesterol are associated with 
increased mortality, thus the amount of cholesterol available to the cells from diet or by de 
novo synthesis needs to be closely regulated. One of the most important coordinators of 
cholesterol homeostasis is the sterol regulatory element-binding protein (SREBP) family of 
transcription factors. Although fundamental mechanisms of the cholesterol metabolism as 
well as their regulation have been well described, it is believed that only a limited number of 
contributing factors have been discovered. 
The aim of this study was to identify novel targets of SREBP that contribute to the tight 
regulation of cellular cholesterol metabolism. For this, ten genes that had not previously 
been associated with cholesterol metabolism, but identified as putative SREBP targets 
through a combination of genome wide gene expression profiling and in silico promoter 
binding site predictions, were experimentally investigated. For nine of these candidate genes 
increased expression under sterol-depleted culture conditions was confirmed. Of these, four 
genes – C17ORF59, HES6, TMEM55B and SLC2A6 – were experimentally validated as 
regulated via SREBP transcription factors. 
One of the most promising candidate genes, C17ORF59, was characterized in further detail to 
elucidate its functional role in cholesterol metabolism. Knockdown of this previously 
uncharacterized gene lead to a redistribution of the low density lipoprotein (LDL) receptor 
from the plasma membrane towards the cell interior. Consequently, cellular uptake of LDL-
cholesterol is considerably reduced. 
Cellular localization studies revealed that the protein C17orf59 predominantly locates to the 
endo-lysosomal system. Furthermore, knockdown of C17orf59 lead to a scattering of the 
Golgi apparatus and is associated with a reduced vesicular stomatis virus glycoprotein (VSVG) 
transport to the cell surface. These results suggest that C17orf59 might play a role in the 
recycling of LDL receptor from sorting endosomes to the plasma membrane. 
By unrevealing C17orf59 as novel SREBP target and as relevant for LDL receptor localization 
and function, the findings of this study may contribute to a better understanding of 
cholesterol metabolism and introduce C17orf59 as putative therapeutic target for 
hypercholesterolemia and arteriosclerosis. 
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ZUSAMMENFASSUNG 
Cholesterin ist ein essentieller Bestandteil zellulärer Membranen höherer Eukaryoten sowie 
Ausgangsprodukt für weitere wichtige Steroide. Da abnormale Cholesterinmengen mit einer 
erhöhten Mortalität assoziiert sind, ist es notwendig zelluläres und systemisches Cholesterin 
genau zu kontrollieren. Ein wichtiger Koordinator dieser Homöostase ist die Familie der sterol 
regulatory element-binding protein (SREBP) Transkriptionsfaktoren. Obwohl grundlegende 
Mechanismen des Cholesterinstoffwechsels und deren Regulation bekannt sind, wird davon 
ausgegangen, dass bisher nur ein Bruchteil der daran beteiligten Faktoren entdeckt wurde. 
Das Ziel dieser Arbeit war es, weitere bislang unbekannte SREBP Targets zu identifizieren. 
Hierzu wurden zehn Gene untersucht welche in einer Genom-weiten Genexpressionsstudie 
sowie durch die Vorhersage von Transkriptionsfaktorbindestellen als putative SREBP Targets 
aufgedeckt wurden. Für neun dieser, bislang nicht mit dem Cholesterinstoffwechsel 
assoziierten Gene, konnte eine erhöhte Expression unter sterol-armen Bedingungen 
nachgewiesen werden. Des Weiteren wurde für die vier Gene C17ORF59, HES6, TMEM55B 
und SLC2A6 der experimentelle Nachweis erbracht, dass diese tatsächlich durch einen 
Transkriptionsfaktor der SREBP Familie reguliert werden. 
Um eine funktionelle Beteiligung am Cholesterinstoffwechsel nachzuweisen, wurde der 
vielversprechendste Kandidat, C17ORF59, genauer charakterisiert. Dabei konnte gezeigt 
werden, dass es bei verminderter Expression dieses Gens zu einer Umverteilung des low 
density lipoprotein (LDL) Rezeptors von der Plasmamembran in das Zellinnere kommt. Dies 
hat zur Folge, dass die zelluläre Aufnahme von LDL-Cholesterin reduziert wird. 
Weitere Untersuchungen zeigten, dass das von C17ORF59 kodierte Protein hauptsächlich im 
endo-lysosomalen System lokalisiert ist. Außerdem konnte nachgewiesen werden, dass bei 
reduzierter Expression von C17orf59 strukturelle Veränderungen am Golgi Apparat auftreten 
und der Transport des vesicular stomatis virus glycoprotein (VSVG) zur Plasmamembran 
beeinträchtig ist. Diese Ergebnisse weisen darauf hin, dass C17orf59 möglicherweise in den 
LDL Rezeptor Recyclingprozess involviert ist. 
Durch das Identifizieren von C17orf59 als neues SREBP Ziel Gen, sowie dessen Relevanz für 
die LDL Rezeptor Lokalisation und Funktion, trägt diese Arbeit zu einem besseren Verständnis 
des Cholesterin Stoffwechsels bei und stellt C17orf59 als ein mögliches therapeutisches 
Target für Hypercholesterinämie und Arteriosklerose vor. 
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Genes and proteins were abbreviated using the official Human Genome nomenclature 
committee symbol (http://www.genenames.org/). 
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1 INTRODUCTION 
1.1 Medical relevance of cholesterol metabolism 
Cardiovascular disease (CVD) is the leading cause of death worldwide (World Health 
Organization, 2011). The most important contributory factor to CVD is arteriosclerosis – a 
chronic disease characterized by the accumulation of lipids and fibrous elements in the large 
arteries (Libby, 2002). While the molecular mechanisms underlying disease manifestation are 
not yet fully understood, cholesterol was one of the first identified risk factors for 
progression of atherosclerotic alterations. In 1910 Windaus showed that atherosclerotic 
plaques consist of calcified connective tissue and cholesterol. At the same time Anitschkow 
and Chaltow were able to induce atherosclerosis in rabbits by feeding a cholesterol-rich diet 
(Mayerl et al., 2006). Until today, multiple genetic and environmental risk factors promoting 
atherosclerotic plaque formation have been identified. These include reduced blood high 
density lipoprotein (HDL) levels, hypertension, diabetes mellitus, elevated levels of 
homocysteine, lipoprotein A or hemostatic factors, insulin resistance, obesity, smoking, high 
fat diet and lack of exercise. Among the risk factors, elevated levels of low density 
lipoproteins (LDL) and very low density lipoproteins (VLDL) play an outstanding role in 
development of atherosclerosis (Glass and Witztum, 2001). It has been shown that excess 
LDL in the blood stream is oxidized over time, leading to the formation of oxLDL (Morel et al., 
1984; Palinski et al., 1989). As a result of oxidation, LDL particles are not recognized anymore 
by the LDL receptor, but instead by scavenger receptors that are expressed on macrophages 
(Sparrow et al., 1989). This results in the development of cholesteryl ester enriched “foam 
cells” - a hallmark of both early and late atherosclerotic lesions (Glass and Witztum, 2001). 
One of the main reasons for high blood concentrations of LDL is the deregulation of 
cholesterol homeostasis, often caused by mutations in several associated genes. The most 
common monogenic defect of cholesterol metabolism known today is familial 
hypercholesterolemia (FH) (Ikonen, 2006). Most cases are inherited in an autosomal 
dominant manner and caused by mutations in the LDL receptor gene, with the heterozygous 
state affecting ~1 in 500 individuals (Hobbs et al., 1992). In addition, mutations in 
apolipoprotein B-100 (apoB), the ligand of the LDL receptor, or in low density lipoprotein 
receptor adaptor protein 1 (ARH), a protein involved in the internalization of the LDL 
receptor via clathrin-mediated endocytosis, have also been described as genetic causes of FH 
(Vega and Grundy, 1986; Garcia et al., 2001; He et al., 2002). Due to mutations in these genes 
LDL is not efficiently cleared from the blood stream, which results in a 30 – 50 % elevated risk 
INTRODUCTION 
 
 
2 
of coronary artery disease (CAD) by the age of 60 (Stone et al., 1974). Other single gene 
disorders that also impact cholesterol metabolism include mutations in the lysosomal acid 
lipase gene, an enzyme that is essential for hydrolysis of cholesteryl esters in lysosomes. 
Mutations in this gene give rise to the early onset Wolman Disease or the late onset 
cholesteryl ester storage disease (CESD), both resulting in lysosomal accumulation of 
cholesteryl esters as well as triglycerides (Klima et al., 1993; Anderson et al., 1994). 
Importantly, as cholesterol is not able to cross the blood-brain barrier, all cholesterol input 
into the central nervous system (CNS) is provided by de novo synthesis (Dietschy and Turley, 
2001). As the brain is the most cholesterol-rich organ, it is thus not surprising that 
abnormalities in cholesterol homeostasis have also been linked with neurodegenerative 
disorders. Some are a consequence of genetic variations affecting proteins involved in the 
cellular cholesterol homeostasis machinery. This includes Niemann-Pick Type C disease 
(NPC), which is likely caused by accumulation of unesterified cholesterol and other lipids in 
late endosomal organelles (Vanier, 2010). The reason for that are mutations in the late 
endosomal membrane protein Niemann-Pick-Type 1 (NPC1) and the soluble lysosomal 
protein Niemann-Pick-Type 2 (NPC2), which are concomitantly involved in the release of free 
cholesterol from lysosomes (Carstea, 1997; Naureckiene et al., 2000; Infante et al., 2008). 
Furthermore, recent studies suggest that impaired cholesterol biosynthesis may also play a 
role in Huntington’s disease (Valenza et al., 2005). 
Beside these monogenic disorders cholesterol is also associated with various complex 
diseases like Diabetes or Alzheimer disease (Howard, 1987; Puglielli et al., 2003) that occur 
from an interplay of multiple genetic variants and environment. 
All in all, a better understanding of the molecular mechanisms of cholesterol homeostasis is 
urgently required for the prevention, diagnosis as well as targeted therapies that will 
eventually curb mortalities associated with cholesterol metabolism disorders. 
 
 
 
 
Figure 1.1 Chemical structure of cholesterol. Important 
C-atoms are labeled according to IUPAC-numbering. 
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1.2 Cellular physiology of cholesterol metabolism 
1.2.1 Cellular cholesterol biosynthesis 
Cholesterol is an organic molecule consisting of four cyclic rings composed of 27 carbon 
atoms. In addition, cholesterol contains a 3-hydroxyl group attached to C3, a double bond 
between C5 and C6, two methyl groups, located at C10 and C13, and an iso-octyl side chain 
at C17 (Figure 1.1). 
Cholesterol is available to the body either from diet or from de novo synthesis, occurring in 
all mammalian cells. All 27 carbon atoms of cholesterol are derived from acetyl-CoA (Little 
and Bloch, 1950). The synthesis occurs in three main steps. In a first step, isopentenyl 
pyrophosphate is synthesized from acetyl-CoA. This reaction chain takes place in the cytosol, 
beginning with the formation of 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) from acetyl-CoA 
and acetoacetyl-CoA by the action of HMG-CoA synthase. This intermediate is then reduced 
to mevalonic acid, which is catalyzed by the HMG-CoA reductase (HMGCR), an integral 
membrane protein in the endoplasmic reticulum (ER). The synthesis of mevalonic acid is 
irreversible and the committed step of cholesterol biosynthesis (Goldstein and Brown, 1990). 
Mevalonic acid is then converted into isopentenyl pyrophosphate in a three step ATP-
dependent reaction, catalyzed by mevalonate kinase, phosphomevalonate kinase and 
mevalonate-5-pyro-phosphate decarboxylase. In a second step, squalene is synthesized from 
six molecules of isopentenyl pyrophosphate, starting with the isomerization of isopentenyl 
pyrophosphate to dimethylallyl pyrophosphate by the action of isopentenyl-PP isomerase. 
Next, both units condense to form geranyl pyrophosphate, which then reacts with another 
molecule of isopentenyl pyrophosphate to generate farnesyl pyrophosphate. All of these 
condensation reactions are catalyzed by geranyl transferase. Two molecules of farnesyl 
pyrophosphate then react to form squalene by the action of squalene synthase in the 
endoplasmic reticulum. In a third step, squalene is cyclized to cholesterol. First, squalene is 
oxidized to 2,3-oxidosqualene catalyzed by squalene epoxidase, which is then converted by 
lanosterol synthase to a protosterol cation and finally to lanosterol, a key intermediate in 
cholesterol synthesis. Lanosterol is then converted in multiple steps to cholesterol involving 
modifications like the removal of three methyl groups, reduction of a double bond and 
distribution of another double bond. This conversion process involves a series of enzymes, 
including lanosterol 14α-demethylase, sterol C14 reductase, cholesterol C4-methyl oxidase, 
NAD(P)H steroid dehydrogenase, 17β-hydroxysterol dehydrogenase, 3β-hydroxysteroid-
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Δ8,Δ7-isomerase, sterol C5-desaturase, 7-dehydrocholsterol reductase and desmosterol 
reductase. 
The synthesized cholesterol acts as a precursor for other important steroid molecules, 
including bile acids, vitamin D or steroid hormones (e.g. progesterone, testosterone, 
estradiol and cortisol). 
As mentioned above the ER membrane protein HMG-CoA reductase catalyzes the rate-
limiting step in cholesterol biosynthesis. It is therefore not astonishing that this enzyme is 
tightly regulated in several ways. (I) If cellular cholesterol levels are low, HMG-CoA reductase 
gene expression is activated by sterol regulatory element binding proteins (SREBP) (Vallett et 
al., 1996). This regulatory mechanism is common for many genes involved in cholesterol 
metabolism and described in further detail in section 1.2.3. (II) Non-sterol metabolites of the 
HMG-CoA reductase product mevalonic acid reduce the translation rate of HMG-CoA 
reductase at the mRNA level (Nakanishis et al., 1988). (III) After a sterol-induced binding to 
insulin induced gene (INSIG) HMG-CoA reductase is ubiquitinated by the autocrine motility 
factor receptor, E3 ubiquitin protein ligase (gp78) for proteasomal degradation (Sever et al., 
2003; Song et al., 2005). (IV) In addition to the classic end-product feedback regulation, the 
activity of HMG-CoA reductase is also reduced through phosphorylation via AMP-activated 
protein kinase when cellular ATP levels are low (Carling et al., 1987; Sato et al., 1993). 
 
1.2.2 Cellular cholesterol uptake by LDL endocytosis 
The human body obtains cholesterol either from diet or de novo synthesis (1.2.1). To ensure 
cholesterol homeostasis, cholesterol has to be transported between organs and peripheral 
cells. Because of insolubility in water, cholesterol is esterified with long-chain fatty acids and 
packaged within the hydrophobic core of plasma lipoproteins to facilitate transport in the 
blood. The core of such a lipoprotein is composed of cholesteryl esters and triglycerides 
coated with a monolayer of phospholipid as well as unesterified cholesterol and stabilized by 
apolipoprotein (Brown and Goldstein, 1986). Plasma lipoproteins are divided in four major 
classes on the basis of size and composition: very low density lipoproteins (VLDL), 
intermediate density lipoprotein (IDL), low density lipoprotein (LDL), and high density 
lipoprotein (HDL) (Olson and Vester, 1960). The most abundant lipoprotein in human plasma 
is LDL, that delivers cholesterol to the peripheral cells (Brown and Goldstein, 1986). 
Cholesteryl esters are too hydrophobic to pass through membranes, thus they are imported 
by clathrin-mediated endocytosis (Figure 1.2) - a common process for internalization of 
different substances into the cell. Beside LDL particles also transferrin and therefore iron or 
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the epidermal growth factor (EGF) pass the plasma membrane by this mechanism 
(Willingham et al., 1979; Karin and Mintz, 1981). Cholesterol import is initiated by the 
interaction of apolipoprotein B-100, which is a component of the LDL coat, with the LDL 
receptor, located on the surface of cells (Mahley et al., 1977). The high efficiency of 
internalization is assured by clustering of the LDL receptor in so called clathrin-coated pits 
(Anderson et al., 1976; Pearse, 1976). These pits pinch off from the surface to form coated 
vesicles (Roth and Porter, 1964), which then enter the clathrin-mediated endocytic pathway 
by rapidly fusing with sorting endosomes. Due to a drop in pH in this compartment the 
receptor dissociates from LDL and is recycled back to the plasma membrane (Tycko and 
Maxfield, 1982), whereas LDL particles are transported into the endo-lysosomal system, 
where degradation occurs. This leads to the hydrolyzation of cholesteryl esters by the action 
of a lysosomal acid lipase (Goldstein et al., 1975a). The resulting unesterified cholesterol 
crosses the lysosomal membrane with the aid of NPC1 and NPC2 proteins (Infante et al., 
2008). It is then distributed to other membranes, such as the endoplasmic reticulum, plasma 
membrane or mitochondria, by the means of vesicular as well as non-vesicular transport 
systems (Maxfield and Wüstner, 2002). 
Free cholesterol released from lysosomes has four effects: (I) It is incorporated into 
membranes. (II) It inhibits the synthesis of new LDL receptors. (III) It reduces the synthesis of 
HMG-CoA reductase and consequently inhibits the cholesterol synthesis, and (IV) it increases 
the activity of the acyl CoA:cholesterol acyltransferase (ACAT), which synthesizes cholesterol 
esters (Olson, 1998). The feedback regulation of cholesterol is mediated by the sterol 
regulatory element binding proteins (SREBP) and is described in more detail in section 1.2.3. 
The pathway of cellular LDL metabolism was first analyzed by Brown and Goldstein using LDL 
radioactively labeled with the iodine isotope 125Iod. In these studies, the aim was to measure 
the binding and degradation of LDL in cultured human fibroblasts from normal subjects and 
individuals with familial hypercholesterolemia (Brown and Goldstein, 1974; Goldstein and 
Brown, 1974). During this time 125Iod-labeled LDL as well as ferritin-coupled LDL were 
commonly used to visualize the distribution of LDL within the cell (Anderson et al., 1977). 
Later on LDL was labeled with the non-radioactive dye 3,3’-dioctadecylindocarbocyanine 
iodide (DiI) to study the cellular uptake of LDL by fluorescence microscopy (Barak, 1981; 
Reynolds, 1985). This method is still applied today, for example to identify novel regulators of 
cholesterol uptake (Qian et al., 2007; Bartz et al., 2009). 
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Figure 1.2 LDL receptor lifecycle and the uptake of LDL via clathrin-mediated endocytosis. 
- illustrates in a simplified scheme the synthesis of the LDLR in the ER, the subsequent transport 
into the Golgi apparatus, where glycosylation occurs and the translocation to the PM. Accumulated in 
clatrin-coated pits the LDLR binds LDL via apoB (). In clathrin-coated vesicles the ligand-receptor-
complex is transported into sorting endosomes. Due to the acid pH in this subcellular compartment 
LDL dissociates from the receptor (). While the LDLR is recycled back to the PM (), LDL is 
transported into the lysosomes, where degradation occurs (). Free cholesterol is then distributed 
within the cell (). (PM, plasma membrane; ER endoplasmic reticulum) 
 
1.2.2.1 The LDL receptor – a key protein in cellular cholesterol metabolism 
The LDL receptor is a prime example of a mosaic protein, which is encoded by a gene 
resulting through exon shuffling (Gilbert, 1985; Südhof et al., 1985a). The haploid human 
genome contains one single copy of the LDL receptor gene, which is located on chromosome 
19 (Francke et al., 1984). The LDL receptor gene consists of 18 exons, which show a striking 
correlation to the functional domains of the protein (Figure 1.3). The first exon encodes for a 
classical signal sequence consisting of 21 amino acids, which directs the receptor-
synthesizing ribosomes to the endoplasmic reticulum membrane. The signal does not appear 
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in the mature protein since it is cleaved from the receptor immediately after translation 
(Yamamoto et al., 1984). Exons 2-6 encode for the binding domain of the receptor, which is 
located on the external surface of the plasma membrane (Schneider et al., 1983). It consists 
of 292 amino acids that combine seven repeats of a 40 amino acids sequence. Each repeat 
contains six cysteine residues which are disulfide-bonded as well as a cluster of negatively 
charged amino acids near the COOH-terminus (Goldstein et al., 1985). The latter constitute 
multiple binding sites for positively charged residues in the α-helix of apolipoprotein E and B 
(Esser et al., 1988). The next eight exons (7-14) encode for a region that is homologous to a 
portion of the extracellular domain of the EGF precursor (Südhof et al., 1985b). Immediately 
external to the membrane-spanning domain lies the O-linked sugar domain, which contains 
18 serine and threonine residues (Russell et al., 1984). This domain is encoded by a single 
exon (15). Parts of exon 16 and 17 encode for the membrane spanning domain of the LDL 
receptor. Exon 17 and 18 contain the sequence information for the cytoplasmic part of the 
LDL receptor. This consists of 50 amino acids, is strongly conserved among species and is 
important for the formation of clathrin-coated pits (Goldstein et al., 1979; Russell et al., 
1984). In summary the LDL receptor consists of 839 amino acids structured in five domains 
(Figure 1.3) (Yamamoto et al., 1984). 
 
 
 
Figure 1.3 Structure of the LDL receptor. (A) LDL receptor gene (Homo sapiens) (ensemble ID: 
ENSG00000130164), consisting of 18 Exons. (B) LDL receptor protein structure (adapted from (Brown 
and Goldstein, 1985). 
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The LDL receptor is synthesized in the endoplasmic reticulum as a precursor with a molecular 
weight of 120 kDa (Tolleshaug et al., 1982), containing high-mannose N-linked carbohydrate 
chains and the core sugar of the O-linked chains. After translocation to the Golgi apparatus 
processing of N- and O-linked oligosaccharides occurs in a series of distinct compartments. 
The mature protein has a molecular weight of 160 kDa (Cummings et al., 1983). From the 
trans-Golgi network (TGN) the LDL receptor is transported to the plasma membrane, where it 
assembles in clathrin coated pits (Brown and Goldstein, 1986). The LDL receptor is now ready 
to take up LDL particles into the cell via clathrin-mediated endocytosis (1.2.2). The acid pH in 
the sorting endosomes leads to dissociation of the LDL particle from the LDL receptor. The 
latter is sorted via tubular buds of the sorting endosome to recycling endosomes and is 
recycled back to the plasma membrane (Mayor et al., 1993). The LDL receptor makes one 
round trip into and out of the cell every ten minutes, independent whether LDL is bound or 
not. The total life-span of the LDL receptor amounts to 20 hours, before being transported to 
lysosomes for degradation (Goldstein et al., 1979). 
Up to now more than 1,000 sequence variants of the LDL receptor are known 
(http://www.ucl.ac.uk/ldlr/Current/summary.php?select_db=LDLR&show=sum). Relative to 
their influence on LDL receptor structure and function they are classified in different groups. 
Class I mutations lead to a reduced or totally abolished synthesis of the LDL receptor. Class II 
mutations result in a reduced transport from the endoplasmic reticulum to the Golgi 
apparatus. Class III mutations fail to bind LDL normally. Class IV variants fail to cluster in 
coated pits and Class V mutations impair LDL receptor recycling. Besides mutations in the LDL 
receptor gene, also other factors influence LDL receptor homeostasis and this LDL uptake. 
Recently, proprotein convertase subtilisin/kexin type 9 (PCSK9) as well as inducible degrader 
of the low-density lipoprotein receptor (Idol) were identified to increase receptor 
degradation (Maxwell et al., 2005; Zelcer et al., 2009). While PCSK9 primarily binds to the 
extracellular EGF-like domain of the LDL receptor (Zhang et al., 2007), Idol ubiquitinates the 
C-terminal domain of the LDL receptor (Zelcer et al., 2009). 
As the LDL receptor plays such an important role in cholesterol metabolism and defects in 
regulation have a disease relevance, further studies aimed to identify novel genes influencing 
the LDL receptor and therewith LDL uptake (Bartz et al., 2009) (1.3). 
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1.2.3 Regulation of cellular cholesterol homeostasis by SREBPs 
Cholesterol participates in many cellular processes. Besides an involvement in 
transmembrane signalling or the regulation of membrane fluidity, cholesterol is also an 
precursor of other important steroid molecules like vitamin D, bile acids or steroid hormones. 
Mammalian cells obtain cholesterol from diet via LDL uptake from the blood stream (1.2.2) or 
by de novo synthesis (1.2.1). These two mechanisms have to be tightly controlled to avoid 
insufficient or excessive cholesterol amounts, which lead to pathological processes (1.1). The 
most important coordinators of cholesterol homeostasis are the sterol regulatory element-
binding proteins (SREBPs), which belong to a large class of transcription factors containing 
basic-helix-loop-helix-leucine zipper (bHLH-Zip) domains (Brown and Goldstein, 1997). Three 
SREBP proteins are described: SREBP-1a, which is a potent activator of all SREBP-responsive 
genes, SREBP-1c, which preferentially regulates genes required for fatty acid synthesis, and 
SREBP-2, which predominantly activates genes involved in cholesterol biosynthesis. Besides 
target gene selectivity, the three SREBP isoforms also differ in their tissue-specificity as well 
as in the efficiency of their trans-activation domains (Briggs et al., 1993; Hua et al., 1993; 
Shimano et al., 1997, 1999). 
SREBPs control cholesterol homeostasis via a sophisticated end-product feedback system 
(Figure 1.4): SREBP is synthesized as precursor, which localizes to endoplasmic reticulum 
membranes and binds there to the SREBP cleavage-activating protein (SCAP). In cells with 
high sterol levels, the sterol-sensing domain of SCAP binds to the insulin-induced gene 
(INSIG) which retains the SREBP-SCAP-complex in the ER (Yang et al., 2002). When the 
amount of cellular sterols decreases, SCAP-INSIG binding is abolished. Instead SCAP interacts 
with the COPII trafficking machinery and therewith transports SREBP to the Golgi apparatus 
(Sun et al., 2007). Here, a mature form of SREBP (nSREBP) is generated by two subsequent 
proteolytic cleavage events catalysed by two membrane bound enzymes: site-1 protease 
(S1P) and site-2 protease (S2P) (DeBose-Boyd et al., 1999). The biologically active 
transcription factors, containing the bHLH-Zip domains, translocate to the nucleus and bind 
to sterol response elements (SRE) in the promoter region of target genes. Because SREBPs 
are only weak transcription factors on their own, they interact with other universal 
transcriptional regulators, including SP1 and nuclear factor Y (NF-Y) (Sanchez et al., 1995; 
Dooley et al., 1998; Jackson et al., 1998). 
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Figure 1.4: The SREBP pathway. At high cellular sterol levels, the SREBP-SCAP complex binds to INSIG 
and remains in the ER. In the absence of sterols the interaction between SCAP and INSIG is abolished, 
the SREBP-SCAP complex is loaded to COPII vesicles and is transported to the Golgi apparatus. After 
two proteolytic cleavage events, catalysed by Site-1 (S1P) and Site-2 (S2P) proteases, the mature form 
of the transcription factor is transported into the nucleus, where it binds to the SRE elements in the 
promoter region of target genes. From (Espenshade and Hughes, 2007). 
 
 
Besides LDL receptor not only HMG-CoA reductase but almost all enzymes of the mevalonate 
pathway are regulated by SREBP transcription factors (Yokoyama et al., 1993; Vallett et al., 
1996; Sakakura et al., 2001). In addition to cholesterol metabolism SREBPs are also involved 
in the regulation of fatty acid, triglyceride and phospholipid uptake and synthesis (Horton et 
al., 2002). SREBP-1c and SREBP-2 expression is, beside other mechanisms, mediated by a 
feed forward mechanism. The mature form of the transcription factor (nSREBP) binds to SRE 
elements in the promoter region of the SREBF-1c and SREBF-2 genes (Sato et al., 1996; 
Amemiya-Kudo et al., 2000). In contrast, SREBP-1a seems to be constitutively expressed at 
low levels. 
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In addition to SREBPs cholesterol homeostasis is regulated by other factors. This includes the 
nuclear liver X receptors (LXRs) (Willy et al., 1995), which activate genes involved in 
cholesterol efflux, including ABCA1, ABCG1, and ABCG5/8 (Goedeke and Fernández-
Hernando, 2012). Post-transcriptional regulation of cholesterol metabolism includes the 
degradation and phosphorylation of HMG-CoA reductase, Idol-dependent ubiquitination and 
PCSK9-dependent degradation of the LDL receptor (1.2.1 and 1.2.2.1). Recently, several 
groups identified microRNA-33 which post-transcriptionally regulates the expression of key 
genes involved in cholesterol homeostasis (Gerin et al., 2010; Horie et al., 2010; Marquart et 
al., 2010; Najafi-Shoushtari et al., 2010; Rayner et al., 2010). 
 
1.3 Novel insights into cellular cholesterol metabolism 
The analyses of cells from patients with classic monogenic disorders led to the identification 
of fundamental processes in cholesterol metabolism. An outstanding example for this are the 
early studies of Brown and Goldstein with cultured fibroblasts from patients with 
homozygous familial hypercholesterolemia (Goldstein and Brown, 1973; Brown and 
Goldstein, 1974), which led to the discovery of the LDL receptor and later on to the 
identification of receptor-mediated endocytosis – a common process for internalization of 
different molecules into the cell. Furthermore, studies with fibroblasts from patients with 
Wolman’s syndrome or cholesterol ester storage disease revealed the essential role of 
lysosomes in the cellular pathway of the LDL receptor (Goldstein et al., 1975b; Brown et al., 
1976). The starting point of these studies were cellular models with a known phenotype 
whose analyses led to the identification of the underlying genotype. However, this kind of 
studies depend on the availability of disease models, are time consuming and thus lead to 
the identification of only a small number of genes involved in cholesterol metabolism. 
Another disadvantage is their impracticality for analyzing more complex disorders like 
Diabetes, Alzheimer or Cardiovascular disease, for which genetic factors get increasingly 
more relevant. 
The availability of the complete human genome sequence in 2004 (International Human 
Genome Sequencing Consortium, 2004) brought the possibility to analyze the interplay of 
various genes and non-genetic factors involved in disease progression. Different large-scale 
genomic strategies were developed with the aim to identify multiple novel factors that play a 
role in common complex disorders. One approach are genome-wide association studies, that 
examine common genetic mutations in a high number of individuals for identification of 
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variants associated with a particular trait. Recently, this led to the identification of a large 
number of genomic loci that are highly significantly associated with plasma levels of 
triglycerides and total, high-density lipoprotein or low-density lipoprotein cholesterol 
(Aulchenko et al., 2009; Kathiresan et al., 2009; Sabatti et al., 2009; Teslovich et al., 2010). 
However, the molecular mechanisms how most of the novel genes or variants at these loci 
contribute to lipid metabolism remain unclear. Thus, applicable approaches are required to 
follow up large data sets produced by GWAS to reveal the impact of gene variants on 
cholesterol metabolism (Runz, 2012). 
Another strategy for the identification of novel regulators involved in cholesterol 
homeostasis are reverse genetic approaches. In contrast to former studies in cell lines with a 
known phenotype, this method allows to change the expression of specific genes and 
examine the resulting phenotype. The development of such approaches benefits from other 
innovative research tools, including (I) microarray analyses, which allow rapid high-
throughput quantification of gene expression for instance in different cell types, tissues or 
disease phenotypes (Schena et al., 1995), (II) high-throughput fluorescence microscopy, 
which allows also large scale analysis in living cells (Perlman et al., 2004; Neumann et al., 
2006) and (III) RNA interference, which allows the suppress expression of specific genes (Fire 
et al., 1998; Elbashir et al., 2001). 
Novel insights into regulation of cholesterol metabolism came from microarray analyses of 
transgenic SREBP1a and SREBP2 mice together with SCAP knockout mice, which led to the 
discovery of putative novel SREBP target genes (Horton et al., 2003). Further SREBP targets 
were proposed by chromatin immunoprecipitation for analyzing DNA-SREBP interaction in 
combination with either microarray analysis (Reed et al., 2008) or high throughput DNA 
sequencing (Seo et al., 2009, 2011). An approach to systematically analyze gene function was 
the combination of microarray analyses of cells grown under sterol depleted conditions with 
RNA interference and automated high-throughput microscopy, which lead to the 
identification of 20 novel genes with a putative functional relevance in cholesterol 
homeostasis (Bartz et al., 2009). 
The identification of novel genes involved in the complex cellular homeostasis hopefully 
leads to a better understanding of these processes and thus associated diseases. Nonetheless 
it is inevitable to characterize candidates identified by large-scale approaches in more detail 
to validate the screening results and reveal their cellular function. 
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1.4 Preliminary work 
With the aim to reveal novel cholesterol-regulated genes, the groups of Dr. H. Runz (Institute 
of Human Genetics, University Heidelberg) and Dr. R. König (German Cancer Research 
Center, Heidelberg) initiated a genome wide gene expression profiling of sterol depleted cells 
in combination with in silico promoter binding site predictions. 
 
1.4.1 Genome wide gene expression profiling 
In order to identify novel genes involved in cholesterol metabolism the group of Dr. H. Runz 
performed gene expression profiling in (I) Hela cells and (II) human fibroblasts established 
from the skin biopsy of a normo-lipidaemic healthy volunteer. Cells were cultivated either 
under control cell culture conditions or deprived from sterols by culture in lipoprotein-
depleted serum and subsequent treatment with (2-Hydroxypropyl)-ß-cyclodextrin (HPCD). As 
shown in previous studies, these conditions allow for efficient cholesterol extraction from 
culture cells and induce maturation of precursor SREBPs, resulting in increased expression of 
SREBP target genes (Kilsdonk et al., 1995; Nohturfft et al., 2000; Runz et al., 2006). Using 
Illumina Human Sentrix-8 oligonucleotide microarrays the expression pattern of 17,848 
human genes were examined. The bioinformatics analysis of the obtained data was done by 
Anna-Lena Kranz from the group of Dr. R. König (Kranz, 2011). Raw data resulting from 
expression studies of Hela cells were normalized with variance stabilization normalization 
(VSN) (Huber et al., 2002). In contrast, raw data emerging from fibroblast experiments were 
analyzed with the lumi package (Du et al., 2008) in “R” (www.r-project.org) and normalized 
with robust spline normalization (RSN) (Lin et al., 2008). The Rank Product Test was used to 
test both data sets for differentially expressed genes by comparing cells grown under control 
or sterol-depleted conditions (Breitling and Herzyk, 2005). Using a cutoff of false positives 
smaller than 5 % (pfp < 0.05) a total of 189 genes showed statistically significant differential 
expression (Supplement, Table S1). Among these, 42 genes had previously been linked to 
cholesterol and/ or lipid metabolism, which was tested using Gene Ontology terms 
(www.geneontology.org) (Supplement, Table S2). This included 16 out of 22 genes essential 
for cholesterol biosynthesis (1.2.1). 
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1.4.2 In silico promoter binding site predictions 
In silico promoter binding site predictions were performed to find out which of the 189 
differentially expressed genes identified by genome wide gene expression analysis (1.4.1) 
could be targets of SREBP transcription factors. For this the sequences from 10,000 bp 
upstream to 1,000 bp downstream of the transcription start site (TSS) of 32,121 human 
genes (retrieved from NCBI, Build 36.3, ftp://ftp.ncbi.nlm.nih.gov/) were scanned for possible 
SREBP consensus elements. Twenty-one position weight matrices (PWMs) for SREBP1a/ 1c 
and seven PWMs for SREBP2, which were taken from TRANSFAC (Release 12.1) (Matys et al., 
2006), were applied. The promoter screen was conducted with “R” as described in (Rahmann 
et al., 2003; Westermann et al., 2008). 
Previous studies showed that SREBPs typically cooperate with the transcriptional co-
activators SP1 and NF-Y (Sanchez et al., 1995; Dooley et al., 1998; Jackson et al., 1998), while 
they are counteracted by the sterol-dependent transcription factor LXR (Repa et al., 2000). 
Thus, genes predicted as potential SREBP targets were also analyzed regarding to consensus 
elements for SP1, NF-Y and LXR. For this, six PWMs for SP1, five PWMs for NF-Y and four 
PWMs for LXR, also taken from TRANSFAC, were used. Of the 189 differentially expressed 
genes, 99 genes contained one or more putative binding motifs for SREBP1a/ 1c and/ or 
SREBP2 as well as for at least one of the additional three transcription factors (Supplement, 
Table S1). Twenty-one out of the 99 genes have previously been associated with cholesterol 
and/ or lipid metabolism. In summary, the combined analysis of genome wide gene 
expression profiling with in silico promoter binding site predictions revealed 78 novel 
putative SREBP target genes (Figure 3.1). 
These results were compared with ChIP-Seq data for SREBP and NF-Y from the ENCODE 
project (Birney et al., 2007). Target genes were determined using the same settings as for the 
in silico promoter screens and binding sites within a range of 10,000 bp upstream to 1,000 bp 
downstream of the TSS were included in the analysis. The resulting genes were compared 
with the putative SREBP target genes, predicted from gene expression profiling and in silico 
promoter binding site screens. 
A table summarizing the results is shown in the supplement (Table S1). The in silico promoter 
screens and the comparison of results with ENCODE data described here, were all done by 
Anna-Lena Kranz from the group of Dr. R. König (Kranz, 2011). 
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2 MOTIVATION AND AIM OF STUDY 
 
The aim of this study was to identify and characterize novel sterol regulatory element binding 
protein (SREBP) target genes that play a role in cholesterol metabolism. 
The SREBP family of transcription factors is one of the most important coordinators of 
cholesterol homeostasis. Although, cholesterol metabolism has been studied for more than 
50 years, the knowledge about this complex network is far from complete and it is suggested 
that only a limited number of SREBP target genes have been uncovered. 
Thus, in the last years different large-scale genomic strategies were developed to reveal 
novel insights into cholesterol homeostasis. Such approaches offer the possibility to identify 
a larger number of genes in a relatively short time. However, to verify the actual impact on 
cholesterol metabolism of genes identified with these strategies additional experiments are 
necessary. Only further characterization of such genes can provide the required information 
which is needed to understand the complexity of the cholesterol homeostasis in more detail. 
Therefore the aim of this thesis was 
 
1. to experimentally validate preliminary data sets that have directed the identification 
of novel SREBP target genes, using a combination of genome wide gene expression 
profiling and in silico promoter binding site predictions 
 
2. to characterize the most promising candidate – C17ORF59 – in more detail to identify 
its functional role in cholesterol metabolism 
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Figure 3.1 Results of the genome wide gene expression study. Genome wide gene 
expression profiling revealed 189 genes with a sterol-dependent expression either in 
fibroblasts (dark green box) or Hela cells (light green box). For 99 of these genes in silico 
promoter scans predicted one or more putative SREBP binding motifs (gray box). 116 
genes were up- (black), 73 down regulated (gray) under sterol depleted conditions 
(DMEM supplemented with 0.5 % LDS (Hela cells) or 5 % LDS (fibroblasts) and subsequent 
treatment with 1 % HPCD for 3 h). Genes which had not previously been linked to 
cholesterol or lipid metabolism are depicted in bold. Genes also identified as putative 
SREBP targets in previous large scale approaches by alternative strategies are marked with 
an asterisk (*). Genes highlighted by round boxes were chosen for validation experiments. 
3 RESULTS 
The work described here deals with the identification of novel SREBP target genes based on a 
genome-wide gene expression profiling and in silico promoter scans. After validation of the 
preliminary data by quantitative real-time PCR and knockdown experiments in cells, one of 
the most promising candidate genes – C17orf59 – was chosen for further characterization. 
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3.1 Identification of novel SREBP target genes 
One aim of this study was to identify novel SREBP target genes and thus find new factors that 
are highly likely to play a role in cholesterol metabolism. To this end, data from combined 
genome-wide gene expression profiling (described in 1.4.1) and in silico promoter scans 
(described in 1.4.2) were analyzed in further detail in order to shortlist interesting 
candidates. 
 
 
 
 
 
 
Gene expression analysis revealed 189 genes which showed a statistically significant 
differential expression under sterol depleted growth conditions in primary human skin 
fibroblasts and/ or Hela cells (Figure 3.1). Out of these, 99 genes were predicted to contain 
one or more putative binding motifs for SREBP1 and/ or SREBP2 (1.4.2). 67 of these genes 
were up-, 32 down regulated after sterol depletion (Figure 3.1). Out of the 67 upregulated 
genes, 18 were previously classified in at least one out of 39 Gene Ontology (GO) categories 
Figure 3.2 Summary of results from genome wide screening for novel SREBP targets. 
Results of genome wide gene expression profiling and in silico promoter binding site 
predictions were categorized in order to shortlist interesting candidates for validation 
experiments. For extended list of results see supplemented table S1. 
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related to cholesterol and/ or lipid metabolism (Supplement, Table S2). Out of the 49 genes 
not yet linked to cholesterol or lipid metabolism 20 genes were also predicted as putative 
SREBP targets in previous large scale approaches by alternative strategies (Horton et al., 
2003; Reed et al., 2008; Seo et al., 2009; Rosenbloom et al., 2010), whereas the other 29 are 
putative novel SREBP target genes. 
Ten of the 49 genes not previous linked to cholesterol metabolism were chosen to validate 
these results. Five of these genes had been predicted previously and five genes were novel 
putative SREBP target genes (Figure 3.2). 
 
Table 3.1 Gene expression levels of putative new SREBP target genes in sterol-depleted cell lines 
Gene     Fibroblasts Hela cells 
Symbol Name EntrezID ratio   SEM ratio   SEM 
genes regulated in both celllines               
LDLR low density lipoprotein receptor 3949 5.90 ± 0.54 3.47 ± 0.54 
SLC2A6 solute carrier family 2 (facilitated glucose transporter), member 6 11182 3.79 ± 1.20 5.09 ± 1.29 
TMEM55B transmembrane protein 55B 90809 3.43 ± 0.58 2.41 ± 0.69 
TOB1 transducer of ERBB2, 1 10140 3.37 ± 1.03 2.19 ± 0.40 
C17orf59 chromosome 17 open reading frame 59 54785 1.86 ± 0.12 1.58 ± 0.22 
HES6 hairy and enhancer of split 6 55502 1.73 ± 0.28 1.82 ± 0.79 
genes regulated in fibroblasts               
KLF6 Kruppel-like factor 6 1316 4.77 ± 0.69 1.48 ± 0.77 
MAFB v-maf musculoaponeurotic fibrosarcoma oncogene homolog B 9935 3.43 ± 0.92 0.71 ± 0.28 
KLF13 Kruppel-like factor 13 51621 2.10 ± 0.65 0.98 ± 0.18 
genes regulated in Hela cells               
ANGPTL2 angiopoietin-like 2 23452 0.85 ± 0.39 2.94 ± 0.77 
not validated by qRT-PCR               
CPSF1 cleavage and polyadenylation specific factor 1 29894 0.88 ± 0.15 1.03 ± 0.10 
Cells were cultivated either under control conditions (5 % FBS (HeLa cells) or 10 % FBS (fibroblasts)) or 
in sterol-depleted medium (0.5 % LDS (HeLa cells) or 5 % LDS (fibroblasts) for 24 h). In addition sterol 
depleted cells were treated with 1 % HPCD (3 h). Expression levels were determined by qRT-PCR and 
normalized to housekeeping gene RPL19 (n = 3 or 4 experiments). 
 
 
3.1.1 Experimental validation of gene expression data 
Ten genes, ANGPTL2, C17ORF59, CPSF1, HES6, KLF6, KLF13, MAFB, SLC2A6, TOB1 and 
TMEM55B, were selected for validation by quantitative real-time PCR using fibroblasts as 
well as Hela cells. For this, cells were cultivated under control or sterol depleted conditions 
and the gene expression levels of the selected candidates were compared to expression of 
housekeeping gene RPL19 (Table 3.1). 
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Genes with on average ≥ 1.5-fold upregulation in sterol depleted compared to control 
conditions were defined as “hits”. According to this criterion, nine of the ten candidate genes 
showed an increased expression after sterol depletion in at least one of the two cell lines 
analyzed (Table 3.1). Despite considerable variations in some instances, these results support 
the microarray-findings that expression of these genes is indeed increased when the cells 
lack sterols. For five (C17ORF59, HES6, SLC2A6, TOB1 and TMEM55B) of the ten genes tested 
increased expression after sterol depletion was detected in fibroblasts as well as in Hela cells 
(Table 3.1). 
With the aim to find out if this regulation could be mediated by the SREBP family of 
transcription factors, C17ORF59, HES6, SLC2A6, TOB1 and TMEM55B were further analyzed 
by siRNA mediated SREBP knockdown experiments. 
 
 
 
 
 
Figure 3.3 Gene expression after SREBP knockdown in sterol-depleted cells. Hela cells were 
cultivated either under control (5 % FBS) or sterol-depleted (0.5 % LDS for 24 h, plus 1 % HPCD for 3 h) 
conditions and treated with siRNAs against either SREBP-1, SREBP-2 or SREBP-1 and SREBP-2. The 
white bars indicate the normalized gene expression under sterol depleted compared to control 
conditions after treatment with a non-silencing control siRNA. Gene expression after knockdown of 
SREBP-1 (light gray bars), SREBP-2 (dark gray bars) or SREBP-1 and SREBP-2 (black bars) was compared 
and normalized to gene expression in control siRNA treated sterol depleted cells (n = 3 experiments; 
HES6 n = 2). The insert shows SREBP knockdown efficiencies under sterol depleted conditions (0.5 % 
LDS plus 1 % HPCD for 3 hours) (n = 2 – 3 experiments). Expression levels were determined by qRT-PCR 
and normalized to housekeeping gene RPL19 (*p < 0.05; **p < 0.01; ***p <0.001). 
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3.1.2 SiRNA-knockdown validates SREBP-dependent regulation for selected genes  
C17ORF59, HES6, SLC2A6, TOB1 and TMEM55B showed a sterol dependent up regulation in 
two different cell lines which further increases the likelihood that these genes are regulated 
by SREBP transcription factors. In order to test this hypothesis, siRNA mediated SREBP 
knockdown experiments were performed and the gene expression levels of C17ORF59, HES6, 
SLC2A6, TOB1 and TMEM55B were measured. Hela cells were cultivated in control or sterol 
depleted medium and transfected with siRNAs either against SREBP-1, SREBP-2, or a 
combination of both. Subsequently, the expression levels of all five candidates were analyzed 
and compared relative to non-silencing control siRNA. The expression of the LDL-receptor, a 
well characterized and known SREBP target (Yokoyama et al., 1993), was used as a control. 
For four of the five genes tested SREBP knockdown reduced induction of gene expression 
upon sterol depletion (Figure 3.3). 
Among the five genes tested, SLC2A6, a member of the family of sugar-transport facilitators 
(Doege et al., 2000; Lisinski et al., 2001), showed the strongest reduction of gene expression 
after SREBP-2 knockdown as wells as the combined knockdown of SREBP-1 and SREBP-2 
which reduced its expression by 85 %. In contrast, knockdown of SREBP-1 alone showed no 
effect (Figure 3.3), proposing this gene as novel SREBP-2 target. Similarly expression of 
TMEM55B, encoding the enzyme phosphatidylinositol-4,5-bisphosphate 4-phosphatase 
type I, was reduced by ~50 % upon SREBP-2 knockdown or when SREBP-2 was knocked down 
together with SREBP-1 (Figure 3.3). HES6 is a member of the Hairy/Enhancer of split family of 
basic helix-loop-helix transcription factors (Pissarra et al., 2000; Vasiliauskas and Stern, 
2000). SREBP-2 knockdown reduced its expression by ~75 % suggesting it as SREBP-2 target 
gene (Figure 3.3). Finally, C17ORF59, a yet uncharacterized gene, showed a reduction of 
expression by up to 50 % after a combined knockdown of SREBP-1 and SREBP-2 in sterol 
depleted cells (Figure 3.3). Taken together, these experiments provide strong evidence that 
SLC2A6, TMEM55B, HES6 and C17ORF59 are indeed novel SREBP target genes. Importantly 
they validate the combined genome wide gene expression and in silico promoter scan 
approach which suggests a high true-positive rate also for the other putative SREBP target 
genes revealed through these studies. 
Notably, for three (TMEM55B, HES6 and C17ORF59 ) of the five genes tested also other 
studies predicted SREBP bindings sites in the promoter region of these genes (Horton et al., 
2003; Reed et al., 2008; Rosenbloom et al., 2010) (Table 3.2). 
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Table 3.2 Overview of experimentally validated novel SREBP target genes 
        predicted SREBP binding sites 
 
Symbol Name EntrezID chrom. loc. [1] [2] [3] [4] [5] [6] 
C17orf59 chromosome 17 open rading frame 59 54785 17p13.1 x x ns ns ns x 
HES6 hairy and enhancer of split 6 (Drosophila) 55502 2q37.3 x x x ns x ns 
SLC2A6 solute carrier family 2 (facilitated glucose 
transporter), member 6 
11182 9q34 x ns ns ns ns ns 
TMEM55B transmembrane protein 55B 90809 14q11.1 x x x ns ns ns 
Summary of novel predicted SREBP target genes. All four genes showed an upregulation under sterol 
depleted culture conditions in fibroblasts and Hela cells as well as a reduced expression after SREBP 
knockdown analyzed by qRT-PCR. This result was compared with other large scale approaches aimed 
of identifying novel SREBP targets ([1] this work, [2] (Rosenbloom et al., 2010), [3] (Reed et al., 2008), 
[4] (Seo et al., 2009), [5] (Horton et al., 2003)) or cholesterol regulators ([6] (Bartz et al., 2009)) (x = hit; 
ns = not significant). 
 
3.1.3 Validation of screening data suggest a role of C17orf59 in LDL uptake 
The transcriptional regulation of genes by SREBPs provides first evidence that these genes 
could play a role in cholesterol metabolism, however, further experiments to validate this 
hypothesis would be necessary to perform. 
With the aim to identify novel regulators of cellular cholesterol homeostasis, the group of Dr. 
H. Runz combined genome-wide expression profiling with targeted RNAi screening (Bartz et 
al., 2009). To reveal putative functions in cholesterol metabolism a set of ~100 candidate 
genes were probed for relevance on cellular cholesterol levels and the efficiency of low-
density lipoprotein uptake into cells. As a result they identified 20 genes as probably 
immediately relevant for maintaining cellular cholesterol levels and/ or LDL uptake (Bartz et 
al., 2009). One of these hits was the uncharacterized gene C17ORF59 which showed a strong 
transcriptional activation in sterol-depleted Hela cells as well as a significantly reduced 
internalization of DiI-LDL after knockdown with three different siRNAs targeting this gene 
(Supplement, Table S3). As the results of this work proposed C17ORF59 as SREBP target and 
with this promising novel regulator of cellular cholesterol metabolism, this gene was selected 
for in depth characterization. 
For validation of the RNAi screening results, independent DiI-LDL uptake assays were 
performed. Three siRNAs targeting C17orf59 that showed the strongest effect on DiI-LDL 
uptake during RNAi screening (Supplement, Table S3) were chosen and transfected into Hela 
cells to reduce C17orf59 expression levels. As a negative control a non-silencing siRNA was 
used. 48 hours after siRNA transfection, DiI-LDL uptake was analyzed. Under these 
conditions, only siC17orf59-1 revealed a significant reduction of DiI-LDL uptake (Figure 3.4A). 
Conversely, the two other siRNAs (siC17orf59-2 and siC17orf59-3) could not be validated to 
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reduce cellular DiI-LDL levels. However, intracellular DiI-LDL loaded vesicular structures 
looked more scattered after C17orf59 knockdown with these two siRNAs (Figure 3.4A). 
Because screening data revealed three siRNAs with functional effects on DiI-LDL uptake and 
to exclude off-target effects of the working siRNA, knockdown efficiency of the three 
different siRNAs against C17orf59 were tested and optimized by quantitative real-time PCR. 
For this, Hela cells were treated with the three different siRNAs as well as with a control 
siRNA for 48 or 72 hours, respectively. Afterwards C17orf59 gene expression was analyzed. 
These experiments showed a reduction of C17orf59 expression by 40 to 60 % after 48 hours 
siRNA treatment for all three siRNAs (Table 3.3). Importantly, the siRNA that most strongly 
reduced DiI-LDL uptake (siC17orf59-1) also reduced C17orf59 mRNA levels most efficiently 
(Table 3.3). By increasing siRNA treatment to 72 hours knockdown efficiencies could be 
raised for two of three siRNAs (Table 3.3). 
Based on these results the DiI-LDL uptake assay was performed 72 hours after siRNA 
transfection to check if the knockdown efficiency correlates with functional effects. These 
experiments resulted in a distinct reduction of cellular DiI-LDL uptake after knockdown of 
C17orf59 by all three siRNAs (Figure 3.4B). Taken together, these data clearly demonstrate 
that the knockdown of C17orf59 strongly reduces cellular DiI-LDL uptake. 
 
 
 
 
Figure 3.4 DiI-LDL uptake assays after C17orf59 knockdown. Hela cells were cultivated in serum free 
medium supplemented with 0.2 % (w/v) BSA, exposed to 1 % (w/v) HPCD for 45 minutes and stained 
with 50 µg/ ml DiI-LDL for 30 minutes at 4 °C followed by cellular uptake of DiI-LDL for 20 minutes at 
37 °C. Shown are representative automatically acquired images of Hela cells transfected with non-
silencing siRNA or three different siRNAs against C17orf59 for 48 h (A) or 72 h (B) respectively. DiI-LDL 
signal was quantified by the software DetecTiff (n = 2 – 4 experiments) (scale bar = 20 µm). 
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Figure 3.5 Dynamic DiI-LDL uptake 
after C17orf59 knockdown. Dynamics 
of DiI-LDL internalization at 37 °C into 
Hela cells treated with siRNA against 
C17orf59 or a non-silencing control 
followed over time. Representative 
images showing the amount of DiI-LDL 
inside the cell after C17orf59 
knockdown at different time points 
compared to control cells (scale bar = 
20 µm). DiI-LDL particles were 
quantified with the software DetecTiff 
(n = 3 experiments). 
 
LDL uptake is a complex process that involves internalization and transport of LDL particles 
into endo-lysosomal compartments as well as recycling of the LDL receptor back to the 
plasma membrane (1.2.2). Analyzing this process in more detail might give hints at which 
stages of this cycle C17orf59 could be involved in. Therefore the siRNA with the strongest 
effect on DiI-LDL uptake was used to perform a dynamic DiI-LDL uptake assay with different 
time points of internalization. The collected data revealed a significantly reduced DiI-LDL 
uptake in C17orf59 knockdown cells already after 10 minutes of DiI-LDL incubation (Figure 
3.5). This reduction continued close to parallel to control cells until 60 minutes of DiI-LDL 
uptake. Taken together, these results show that C17orf59 influences the uptake of DiI-LDL 
already at an early stage of this event. 
 
 
Table 3.3 Knockdown efficiencies of siRNAs against C17orf59 
 48 h knockdown 72 h knockdown 
siRNA mean  SD mean  SD 
siC17orf59-1 0.41 ± 0.21 0.26 ± 0.08 
siC17orf59-2 0.51 ± 0.03 0.34 ± 0.11 
siC17orf59-3 0.58 ± 0.15 0.65 ± 0.15 
 
Hela cells were transfected with the listed siRNAs for 
indicated times. One day before the experiment medium was 
changed to DMEM + 0.2 % BSA. In addition cells were treated 
with 1 % HPCD for 45 minutes. Expression levels were 
determined by qRT-PCR and normalized to housekeeping gene 
RPL19 (n = 4 - 6 experiments). 
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LDL is taken up into the cell via receptor mediated endocytosis (1.2.2). Besides LDL also other 
molecules, such as transferrin or growth factors, use this process for passing the hydrophobic 
plasma membrane (Willingham et al., 1979; Karin and Mintz, 1981). To determine if the 
effect on the LDL uptake after C17orf59 knockdown is specific or caused by a general 
impairment of endocytosis, uptake of transferrin was analyzed. For this, Hela cells were 
transfected with siC17orf59-1 and as positive control a siRNA targeting the transferrin 
receptor. Transferrin uptake was monitored by fluorescence microscopy using transferrin 
labeled with Alexa Fluor® 568 (Tf-568). The internalized amount of transferrin was inspected 
on the microscope and analyzed with the software DetecTiff. Knockdown of C17orf59 did not 
significantly reduce transferrin uptake, although a slightly decreased internalization could 
also be seen for Tf-568 (Figure 3.6). This result suggests that endocytosis in general is not 
impaired by reduction of C17orf59 and that observed effects could be specific to LDL uptake. 
In summary, these data provide convincing evidence that C17orf59 is a novel regulator of LDL 
uptake into cells. In the following section further functional analyses are described to confirm 
this hypothesis. 
 
 
Figure 3.6 Transferrin uptake after C17orf59 knockdown. Hela cells were labeled with 100 µg/ ml 
Tf568 at 4 °C for 30 minutes followed by incubation with 300 µg/ ml Apotransferrin for 15 minutes at 
37 °C before fixation. Shown are representative automatically acquired images of Hela cells 
transfected for 72 h with non-silencing control siRNA, siRNA known to reduce transferrin uptake 
(TFRC) or siRNA against C17orf59. The Tf-568 signal was quantified by the software DetecTiff (n = 4 
experiments; TFRC n = 1) (scale bar = 20 µm). 
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3.2 Functional characterization of the protein C17orf59 
The so far obtained results provide good reasons to assume that C17orf59 has a role in 
cellular cholesterol homeostasis. In order to determine this hypothesized function, a cell 
biological characterization of this gene in relation to the sterol metabolism was conducted. 
As C17orf59 represents a hitherto uncharacterized gene/ protein, this study started by 
determining basic features for it. This included tissue expression (3.2.1) and expression 
regulation (3.2.2), determination of protein conservation (3.2.3) and subcellular localization 
(3.2.4). In addition, it was tested whether overexpression of C17orf59 protein could rescue 
C17orf59 knockdown effects on LDL uptake (3.2.5). In order to find out the mechanisms by 
which C17orf59 reduce DiI-LDL uptake, impact of C17orf59 on the LDL receptor was 
investigated in more detail (3.2.6). Furthermore, effects of C17orf59 knockdown on general 
cellular processes were analyzed (3.2.7). 
 
3.2.1 C17orf59 mRNA is generally expressed at low levels 
The gene C17ORF59 is localized on chromosome 17p13.1. The gene structure comprises only 
a single exon. However, two known gene variants exist (Ensembl database (release 54 – May 
2009)). The longer one consists of 1,074 bp (reference number NM_017622, referred to as 
transcript-1), the shorter one of 672 bp (reference number BC018880, referred to as 
transcript-2). The sequence of the short transcript corresponds to the 3’-end of the longer 
isoform, proposing different transcription start sites (Figure 3.7). The translation start site of 
transcript-2 is located at position 403 of transcript-1. 
 
 
 
 
 
Figure 3.7 Graph of the human C17orf59 gene. Depicted are both known isoforms and the in 
silico predicted SRE-1 element 5’ of the transcription initiation site. 
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Table 3.4 C17orf59 expression levels in  
different cell lines. 
cell line mean (CT)  SD 
HeLa kyoto 31.67 ± 0.62 
Fibroblasts 31.30 ± 2.18 
HuH7 31.99 ± 1.28 
HEK293 32.17 ± 0.72 
SH-SY5Y 30.90 ± 3.91 
Cells were cultivated in cell line specific 
medium (Table 6.16). After reaching a 
confluency of ~90 % RNA was isolated, 
gene expression of C17orf59 was 
determined by qRT-PCR and 
normalized to housekeeping gene 
RPL19 (n = 3 experiments). 
In silico promoter binding site predictions (1.4.2) 
revealed a SREBP binding site (SRE-element) 
~3,800 bp upstream of the transcription start site 
(TSS) of transcript-1. In addition, ChIP sequencing 
experiments indicate a second SRE-element directly 
preceding the TSS (Rosenbloom et al., 2010), 
consistent with C17orf59 being a novel SREBP target 
(3.1.2). 
In the qRT-PCR validation experiments (3.1.1) it was 
striking that C17orf59 showed only a low gene 
expression rate in Hela cells and fibroblasts (Table 
3.4). It was therefore possible that C17orf59 could 
show in general a weak basic expression rate. With a 
role in cholesterol homeostasis C17orf59 could be 
expressed at higher levels in cell types which are key 
components of cholesterol metabolism, such as liver 
and brain. To address this, expression levels of 
C17orf59 were tested in three other cell lines, 
including HEK293 (embryonic kidney cells), HuH7 
(hepatocyte derived cellular carcinoma cells) and 
SH-SY5Y (a neuroblastoma cell line) cells. All cells 
were cultivated in cell line specific growth medium 
(Table 6.16). After reaching a confluence of ~90 % 
total RNA was isolated and C17orf59 expression 
levels were quantified by qRT-PCR. As shown in 
Table 3.4, gene expression of C17orf59 was also low 
in HEK293, HuH7 and SH-SY5Y cells with comparable 
levels as in Hela cells and fibroblasts (Table 3.4). 
The five cell lines tested cover only a small part of 
human tissues and thus do not allow for general 
conclusions on C17orf59 expression. Therefore, RNA 
from 20 different tissues, using the First Choice 
Human Total RNA Survey Panel from Ambion, were 
tested for C17orf59 levels by qRT-PCR. The data 
Table 3.5 C17orf59 expression levels in 
different human tissues. 
tissue CT-value 
trachea 31.48 
thyroid 30.61 
small intestine 30.91 
testis 30.91 
spleen 29.72 
ovary 30.83 
prostate 32.46 
thymus 30.01 
skeletal muscle 29.62 
bladder 30.98 
esophagus 31.48 
kidney 29.72 
cervix 31.31 
adipose 31.94 
heart 31.81 
brain 29.88 
liver 31.94 
placenta 31.02 
lung 31.55 
colon 31.37 
RNA from the First Choice Human Total 
RNA Survey Panel from Ambion was 
analyzed by qRT-PCR to determine 
C17orf59 expression levels. The values 
were normalized to housekeeping gene 
RPL19 (n = 1 experiment; done by Luise 
Kern). 
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revealed that in all analyzed tissues gene expression of C17orf59 ranges between a CT-value 
of 29.6 in skeletal muscle and 32.5 in prostate (Table 3.5), corresponding to low expression 
levels in tested cell lines (Table 3.4). It can therefore be concluded that C17ORF59 is a gene 
with an in general low basic expression rate. 
None of the conducted experiments revealed a cell line or tissue with a significantly higher 
C17orf59 expression than Hela cells (Table 3.4 and 3.5). Therefore and since preliminary 
functional results were also obtained in Hela cells, this cell line was also used to characterize 
C17orf59 further. 
 
 
 
 
3.2.2 Expression of C17orf59 is up regulated under sterol depleted conditions 
Despite a low basic expression rate, the qRT-PCR validation experiments revealed a sterol 
dependent upregulation of C17orf59 mRNA levels in Hela cells and fibroblasts (3.1.1, Figure 
3.9, A). 
In order to test C17orf59 expression on the protein level, western blot experiments were 
carried out. As no commercial antibody existed against C17orf59 protein C17orf59 
expression constructs for bacterial expression were generated, full length protein was 
purified with the help of the EMBL Protein Expression and Purification Core Facility and a 
rabbit polyclonal antibody was generated with the help of a company. As antigen, C17orf59 
translation product 2 was used, so that the resulting antibody would bind to both known 
Figure 3.8 C17orf59 antibody test. For 
checking the newly generated 
antibody against C17orf59 lysates of 
Hela cells, C17orf59 knockdown cells 
and cells overexpressing pEGFP-N2-
C17orf59-T2 were analyzed by western 
blot. B-actin was used as an internal 
control. 
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C17orf59 isoforms. To test the resulting antibody, lysates of normal Hela cells, C17orf59 
knockdown cells as well as cells which overexpress pEGFP-N2-C17orf59-T2 were analyzed by 
western blot. This test showed that the generated antibody detected both bioinformatically 
predicted endogenous C17orf59 protein isoforms as well as the overexpressed pEGFP-N2-
C17orf59-T2 construct at the expected height (Figure 3.8). Furthermore, the western blot 
revealed a ~3-fold higher expression of the longer C17orf59 transcript compared to the 
expression of the shorter one (Figure 3.8). Under C17orf59 knockdown conditions protein 
levels of both endogenous C17orf59 isoforms were reduced (Figure 3.8), which suggests that 
the antibody was specific. 
The antibody was then used to analyse C17orf59 protein levels during lack of sterols. For this, 
Hela cells were cultivated under control or sterol depleted conditions. After reaching a 
confluency of ~90 % the cells were lysed and analyzed. The results revealed a moderate 
upregulation after sterol depletion for both C17orf59 protein isoforms (Figure 3.9, B, C). 
These data strengthen the results of the mRNA expression analysis and confirm an 
upregulation of C17orf59 when the cells lack sterols. 
 
 
 
 
Figure 3.9 Comparison of C17orf59 mRNA and protein levels under control and sterol-depleted 
conditions. (A) C17orf59 mRNA level in fibroblasts and Hela cells under control ((5 % FBS (HeLa cells) 
or 10 % FBS (fibroblasts)) and sterol depleted conditions (0.5 % LDS (HeLa cells) or 5 % LDS 
(fibroblasts)). In addition sterol depleted cells were treated with 1 % HPCD (3 h). Expression levels 
were determined by qRT-PCR and normalized to housekeeping gene RPL19 (n = 3 - 4 experiments). (B) 
Representative western blots showing C17orf59 protein levels at control as well as sterol depleted 
conditions. Β-actin was used as internal control. (C) Quantification of C17orf59 protein level from 
western blot experiments using ImageJ (n = 3 experiments) (* p < 0.05; ** p < 0.01). 
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3.2.3 C17orf59 is highly conserved in mammals 
Western blot experiments revealed that two C17orf59 protein isoforms exist in cells (Figure 
3.8, Figure 3.9). 
Transcript-1 encodes for a protein of 357 amino acids. This implies a size of ~40 kDa. On a 
NuPAGE 4-12 % Bis-Tris gel the protein is detectable between 40 and 50 kDA. Transcript-2 
consists of only 223 amino acids corresponding to a hypothetical size of ~25 kDa. This 
transcript appears between 25 and 30 kDa on a NuPAGE 4-12 % Bis-Tris gel. Both C17orf59 
versions exhibit a predicted prolin-rich region as well as a predicted coiled-coil structure at 
the 3’-end. In addition, for both isoforms an N-terminal domain of adenylylcyclase associated 
protein (CAP) is predicted (Ensembl database (release 54 – May 2009)) (Figure 3.10). 
Analysis of C17orf59 protein conservation revealed that this protein is to more than 80 % 
conserved in mammals (Figure 3.10, Supplement Figure S1). It was also obvious that the 3’-
end of the protein, which contains both transcripts and all predicted domains, is more 
conserved than the 5’-end of the protein. 
 
 
 
 
 
Figure 3.10 C17orf59 protein sequence. Depicted are both C17orf59 
protein isoforms, predicted domains and the amino acid conservation in 
vertebrates, based on calculations in relation to selected eutherian 
mammal species (Supplement, Figure S1). 
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Figure 3.11 C17orf59-T2-EGFP localization under normal culture conditions. Hela cells stably 
expressing pEGFP-N2-C17orf59-T2 were cultured in normal growth medium (DMEM + 5 % FBS). After 
fixation the cells were co-stained with antibodies against LAMP1, EEA1 and GM10. As secondary 
antibody anti-mouse Cy3 was used. The samples were imaged with a confocal microscope. Depicted 
are maximum projections of 20 images per channel. To check possible co-localization both channels 
were merged (lane 3) (scale bar = 10 µm). 
 
3.2.4 C17orf59 localizes to late endo-lysosomal compartments 
Knowledge about protein localization within the cell is important for understanding protein 
function. To find out in which cellular compartments C17orf59 is localized the generated 
antibody against this protein (3.2.2) was tested in immunofluorescence experiments. 
However, despite several attempts to optimize staining conditions, the antibody was not 
working for this kind of application, possibly because C17orf59 levels inside the cell are too 
low for recognition. Thus, to allow visualization within cells the shorter, but more conserved 
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version of C17orf59 was C-terminally fused to the enhanced green fluorescent protein 
(EGFP). The resulting plasmid (pEGFP-N2-C17orf59-T2) was stably transfected into Hela cells 
to identify C17orf59-EGFP localization inside the cell. After selection of a C17orf59-EGFP 
stably expressing Hela cell line these cells were cultivated under normal growth medium 
conditions, fixed and co-stained with antibodies against different cellular organelle marker 
proteins, e.g. LAMP1, a lysosomal membrane protein, EEA1, the early endosome antigen 1 
protein and GM130, a cis-Golgi matrix protein. The samples were analyzed and imaged with a 
confocal microscope. The detected GFP signal revealed a large overlap of C17orf59-T2-EGFP 
with the lysosomal marker protein LAMP1. Conversely, no co-localization with EEA1 or 
GM130 could be observed (Figure 3.11). To a smaller extent, C17orf59-T2-EGFP was also 
found in the cytosol (Figure 3.11). 
The previous results suggested that C17orf59 could be particularly important for cellular 
cholesterol metabolism when the cell lacks sterols (3.1.3). This is strengthened by expression 
studies showing that C17orf59 mRNA and protein levels are upregulated under sterol 
depleted conditions (3.2.2). Therefore, localization of C17orf59-T2-EGFP was also analyzed 
under these conditions. For this purpose Hela cells stably expressing pEGFP-N2-C17orf59-T2 
were cultivated in sterol depleted medium. After fixation cells were co-stained with 
antibodies against LAMP1, EEA1 or GM130. Like under control conditions (Figure 3.11), the 
images revealed a co-localization of C17orf59-T2-EGFP with LAMP1 also after sterol 
depletion. In contrast EEA1 and GM130 did not overlap with overexpressed C17orf59-T2-
EGFP also under these conditions (Figure 3.12). 
As it was unclear if both or only one of the two C17orf59 isoforms was relevant for 
cholesterol metabolism, the localization of the longer isoform of C17orf59 was also tested. 
To study this, also C17orf59-T1 was tagged with EGFP at the C-terminus and the resulting 
plasmid (pEGFP-N2-C17orf59-T1) was transiently transfected into Hela cells. After cultivation 
in normal culture media cells were co-stained with an antibody against LAMP1. Microscopy 
images revealed a point-shaped structure around the nucleus where also lysosomes can be 
found (Figure 3.13). However, it was not so obvious that both fluorescence signals were 
overlapping. 
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Figure 3.12 C17orf59-T2-EGFP localization under sterol depleted conditions. Hela cells stably 
expressing pEGFP-N2-C17orf59-T2 were cultured at sterol depleted conditions (DMEM + 0.5 % LDS for 
24 h, + 1 % HPCD for 45 minutes). After fixation cells were co-stained with antibodies against LAMP1, 
EEA1 and GM10. As secondary antibody anti-mouse Cy3 was used. The samples were imaged with a 
confocal microscope. Depicted are maximum projections of 20 images per channel. To check possible 
co-localization both channels were merged (lane 3) (scale bar = 10 µm). 
 
In addition to Hela cells the localization of both C17orf59 transcripts were also analyzed in 
HuH7 cells, which are considered as a functionally more relevant model for cholesterol 
homeostasis. For this, the EGFP tagged C17orf59 constructs were transiently transfected into 
HuH7 cells which were then cultivated under normal growth conditions. 24 hours after 
transfection cells were fixed and the lysosomal protein LAMP1 was stained with the 
respective antibody. The samples were then analyzed by confocal microscopy. Thereby the 
longer version of C17orf59 shows a high overlap with the LAMP1 signal, whereas the shorter 
one co-localizes only partially with this marker in HuH7 cells (Figure 3.14). 
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Figure 3.13 Localization of C17orf59-T1-EGFP in Hela cells. Cells were transient transfected with 
pEGFP-N2-C17orf59-T1 and cultivated at control conditions (DMEM + 5 % FBS). After fixation cells 
were co-stained with an antibody against the lysosomal protein LAMP1 as well as with the secondary 
antibody anti-mouse-Cy3. Depicted are maximum projections of confocal microscopy images. To check 
possible co-localization both channels were merged (lane 3) (scale bar = 10 µm). 
 
Although fluorescent protein fusions of C17orf59 showed a good indication that this protein 
localizes to lysosomes, it cannot be excluded that the fluorescent tag alters the location of 
the native protein. As the generated antibody against C17orf59 did not work for immune 
fluorescence staining but can detect the native protein in western blot experiments (Figure 
3.8), subcellular fractionation was used as additional method to confirm C17orf59 
localization and thereby reduce overexpression artifacts. With the aim to separate lysosomes 
from other cellular compartments a simplified organelle fractionation protocol resulting in 
four different cellular fractions was used (see material and methods 6.3.7). For this, a huge 
amount of Hela cells was seeded, grown at normal culture medium and harvested after 
reaching a confluency of ~90 %. The cells were than homogenized and centrifuged in two 
steps. This resulted in four different cellular fractions. The first fraction (A) should contain the 
whole homogenized cell lysate. Fraction B should be enriched for mitochondria. Lysosomes, 
microsomes and peroxisomes should be found in fraction D. And fraction E should include 
microsomes as well as the soluble cytosolic proteins. The obtained fractions were than 
analyzed by western blot. As control the lysosomal marker protein LAMP1 was used, which 
as expected could be detected in the lysosmal fraction D (Figure 3.15). Consistent with the 
findings with overexpressed C17orf59-EGFP both endogenous C17orf59 isoforms were also 
most abundant in this fraction, although transcript-1 was to a lower amount also detectable 
in other fractions (Figure 3.15). These results support the localization data obtained by 
overexpression of C17orf59 tagged with fluorescent protein in different cell lines (Figures 
3.11, 3.12 3.13 and 3.14). In summary the results strongly suggest that C17orf59 localizes to a 
significant extent to endo-lysosomal compartments. 
RESULTS 
 
 
34 
 
Figure 3.14 C17orf59 localization in HuH7 cells. Cells were transient transfected with pEGFP-N2-
C17orf59-T2 (upper lane) or pEGFP-N2-C17orf59-T1 (lower lane) and cultivated at control conditions 
(DMEM + 10 % FBS). After fixation cells were co-stained with an antibody against the lysosomal 
protein LAMP1 as well as with the secondary antibody anti-mouse-Cy3. Depicted are maximum 
projections of confocal microscopy images. To check possible co-localization both channels were 
merged (lane 3) (scale bar = 10 µm). 
 
 
 
Figure 3.15 Identification of C17orf59 localization by subcellular fractionation. After homogenization 
Hela cells were fractionated by different centrifugation steps. The resulting fractions were analyzed by 
western blot. Fraction A comprised the whole homogenized cell lysate, fraction B contained 
mitochondria, fraction D included lysosomes, microsomes and peroxisomes, fraction E contained 
microsomes and the soluble fraction. As control the lysosmal protein LAMP1 was used. 
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3.2.5 Rescue of the C17orf59 knockdown effect on LDL uptake 
In a high-throughput RNAi screening C17orf59 was identified as possible regulator of the 
cellular LDL uptake (Bartz et al., 2009). This evidence was strengthened by independent 
validation experiments with three different siRNAs (3.1.3). A potential role of C17orf59 for 
LDL uptake is also supported by the results of the localization studies, which showed that 
most of C17orf59 protein resides in endo-lysosomal compartments (3.2.4). These organelles 
play an important role in uptake and distribution of newly internalized LDL-derived 
cholesterol (1.2.2). 
 
 
Figure 3.16 DiI-LDL uptake after C17orf59 overexpression and knockdown efficiency as well as DiI-
LDL uptake test for siC17orf59-4. (A) DiI-LDL levels in Hela cells stably expressing pEGFP-N2-C17orf59-
T2 compared to control cells without C17orf59-EGFP signal. Hela cells were cultivated in serum free 
medium supplemented with 0.2 % (w/v) BSA, exposed to 1 % (w/v) HPCD for 45 minutes and stained 
with 50 µg/ ml DiI-LDL for 30 minutes at 4 °C, followed by cellular uptake of DiI-LDL for 20 minutes at 
37 °C. 100 cells per condition (n = 2 experiments) were randomly selected and marked manually. DiI-
LDL intensity per cell was determined with the software ImageJ. (B) Knockdown efficiency test for 
siC17orf59-4 targeting C17orf59 UTR. Hela cells were transfected with either non-silencing siRNA or 
siC17orf59-4 for 72 hours. C17orf59 expression levels were determined by qRT-PCR and normalized to 
housekeeping gene RPL19 (n = 7 experiments). (C) DiI-LDL levels in Hela cells transfected with control 
siRNA or siC17or59-4. Cells were treated as mentioned in (A). DiI-LDL signal was quantified by the 
software DetecTiff (n = 4 experiments). 
 
For demonstrating that the observed reduction in DiI-LDL uptake specifically caused by 
knockdown of C17orf59, several strategies for rescue experiments were conducted. In a first 
approach knockdown of endogenous C17orf59 was performed with a siRNA binding to the 
untranslated region (UTR) of the gene. The idea was to counter the resulting RNAi phenotype 
by overexpression of pEGFP-N2-C17orf59-T2, which should be resistant to silencing by the 
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siRNA binding to the UTR of endogenous C17orf59. Prior to this the possible effect of 
overexpressed C17orf59-EGFP on DiI-LDL uptake was analyzed. For this the assay was 
performed in Hela cells stably expressing pEGFP-N2-C17orf59-T2. The endosomal DiI-LDL 
amount of cells overexpressing C17orf59-EGFP was than compared to those which did not 
overexpress this construct. The analysis revealed that overexpression of pEGFP-N2-C17orf59-
T2 has no effect on DiI-LDL uptake. The amount of cellular DiI-LDL in C17orf59 overexpressing 
cells was nearly the same as in control cells (Figure 3.16A). 
In a next step knockdown efficiency and effect on DiI-LDL uptake by the C17orf59 UTR 
binding siRNA (siC17orf59-4) was tested. QRT-PCR analysis of C17orf59 mRNA levels after 
siRNA mediated knockdown using siC17orf59-4 revealed a reduced gene expression of 
C17orf59 by 85 % after 72 hours (Figure 3.16B). After demonstrating that the siRNA 
sufficiently reduces C17orf59 mRNA its influence on DiI-LDL uptake was examined 72 hours 
after transfection. The samples were imaged by automated microscopy and analyzed with 
the software DetecTiff. However, despite efficient C17orf59 knockdown, no visible effect on 
DiI-LDL uptake was detectable (Figure 3.16C). It was therefore not possible to use this siRNA 
for rescue experiments. 
As validation experiments showed that knockdown of C17orf59 with three other siRNAs 
strongly reduced LDL uptake, another rescue strategy was followed. For this the siRNA with 
the most pronounced effect on DiI-LDL uptake (siC17orf59-1) was used to silence C17orf59. 
To rescue reduced DiI-LDL uptake upon C17orf59 knockdown a C17orf59-EGFP construct 
which had been made resistant to the silencing siRNA was co-expressed. In order to achieve 
this, one silent mutation was introduced at the binding site of siC17orf59-1 in the C17orf59 
sequence by site-directed mutagenesis. 
To test the functionality of this approach Hela cells were first transfected with three siRNAs 
against C17orf59 (siC17orf59-1, siC17orf59-2, and siC17orf59-3) in order to co-transfect 
those 48 hours after knockdown either with wild-type pEGFP-N2-C17orf59-T2 or mutated 
pEGFP-N2-C17orf59-T2_C555T. 24 hours later the cells were lysed and examined by western 
blot. Analysis of the protein amount of endogenous as well as overexpressed C17orf59 
revealed on the one hand, that all three siRNAs used are functional, as there application led 
to a reduced expression of both endogenous C17orf59 transcripts as well as of the wild-type 
C17orf59-EGFP construct (Figure 3.17A, B). On the other hand it was visible that siC17orf59-2 
and siC17orf59-3 also reduced the mutated pEGFP-N2-C17orf59-T2_C555T construct 
whereas siC17orf59-1 could not lower its expression. The mutated C17orf59-EGFP protein 
showed after treatment with siC17orf59-1 similar expression levels as under control 
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conditions (Figure 3.17A, B). Thus, siC17orf59-1 reduces the expression of endogenous but 
not mutated overexpressed C17orf59, which is the basis for the rescue experiment. 
To test this approach also for the DiI-LDL uptake assay, Hela cells were treated with 
siC17orf59-1 or a non-silencing siRNA. After 48 hours the mutated pEGFP-N2-C17orf59-
T2_C555T construct was co-transfected. After performance of the DiI-LDL uptake assay, 
images were acquired by automated microscopy and single cells were analyzed as to their 
C17orf59-EGFP and DiI-LDL levels. For this 40 cells per condition were manually marked and 
the mean intensity of the DiI-LDL as well as the EGFP signal per cell was measured with 
ImageJ. As expected, analysis of these data revealed that in control cells, which did not 
overexpress C17orf59-EGFP but were treated with siC17orf59-1 the amount of DiI-LDL was 
reduced (Figure 3.17C). Cells which contained mutated pEGFP-N2-C17orf59-T2_C555T and 
were in addition treated with a control siRNA showed nearly the same amount of DiI-LDL as 
in control cells without C17orf59-EGFP (Figure 3.17C). This confirmed the data analyzed 
before, which showed that overexpression of C17orf59-EGFP did not influence DiI-LDL uptake 
(Figure 3.16A). Comparison of C17orf59 knockdown cells containing overexpressed mutated 
pEGFP-N2-C17orf59-T2_C555T versus these missing this construct showed no significant 
difference in the DiI-LDL amount. It can thus be concluded that in this case the rescue was 
not working. It was not possible to restore the DiI-LDL amount as under control conditions. 
Despite using two different approaches, rescue of the DiI-LDL uptake effect after C17orf59 
knockdown could not be achieved. 
 
3.2.6 Reduction of C17orf59 induces re-localization of the LDL receptor 
In order to find out how knockdown of C17orf59 could reduce the uptake of LDL, its effects 
on the LDL receptor, a key component in this process (see 1.2.2.1), was analyzed in further 
detail. 
First, it was checked if reduced levels of C17orf59 influenced on LDL receptor mRNA 
expression or protein amount. For this LDL receptor mRNA levels were measured by qRT-PCR 
after C17orf59 knockdown in Hela cells grown under sterol depleted conditions. As control 
the expression levels of HMGCR, a key enzyme in the synthesis of cholesterol, were also 
determined. These experiments showed that knockdown of C17orf59 reduced mRNA 
expression of the LDL receptor by about 35 % whereas HMGCR levels were reduced by about 
30 % (Figure 3.18A). Interestingly, not only knockdown of C17orf59, but also overexpression 
reduced LDL receptor expression to similar levels at the conditions tested (Figure 3.18A). 
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Figure 3.17 Test if pEGFP-N2-C17orf59-T2_C555T is able to rescue C17orf59 knockdown effects. 
(A) Western blot showing lysates from Hela cells transfected with either siC17orf59-1, siC17orf59-2, 
siC17orf59-3 or a non-silencing control siRNA and overexpressing either pEGFP-N2-C17orf59-T2 or 
pEGFP-N2-C17orf59-T2_C555T. C17orf59 protein levels were analyzed and normalized to ß-actin. 
(B) Quantification of C17orf59 protein level from western blot experiments using ImageJ (n = 1 
experiment). (C) Quantification of DiI-LDL uptake rescue after C17orf59 knockdown and 
overexpression of pEGFP-N2-C17orf59-T2_C555T. Hela cells were cultivated in serum free medium 
supplemented with 0.2 % (w/v) BSA, exposed to 1 % (w/v) HPCD for 45 minutes and stained with 
50 µg/ ml DiI-LDL for 30 minutes at 4 °C followed by cellular uptake of DiI-LDL for 20 minutes at 
37 °C. For quantification 40 cells per condition were manually marked and the mean intensity of the 
DiI-LDL was measured with ImageJ. 
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Figure 3.18 LDLR mRNA and protein levels in response to changing cellular C17orf59 levels. (A) LDLR 
and HMGCR mRNA levels after C17orf59 knockdown or overexpression. Hela cells were cultivated in 
sterol depleted medium (DMEM supplemented with 0.5 % LDS for 24 h, plus 1 % HPCD for 45 
minutes). Expression levels were determined by qRT-PCR and normalized to housekeeping gene RPL19 
(n = 3 – 5 experiments). (B) Representative western blots showing LDLR protein amount after C17orf59 
knockdown or overexpression. Β-actin was used as internal control. (C) Quantification of LDLR protein 
level from western blot experiments using ImageJ (n = 3 experiments) (* p < 0.05; ** p < 0.01). 
 
Furthermore the LDL receptor protein amount after C17orf59 knockdown or overexpression 
was determined by western blot experiments. Therefor C17orf59 siRNA or cDNA transfected 
Hela cells were cultivated under sterol depleted conditions in DMEM supplemented with 
0.5 % LDS. Cells were in addition treated with 1 % HPCD for 45 minutes. The western blot 
analysis revealed slightly but not significant reduced levels of LDL receptor after C17orf59 
knockdown as well as after overexpression of this gene. However, this effect alone cannot 
explain the reduced DiI-LDL uptake by about 80 % after C17orf59 knockdown (3.1.3). 
Besides LDL receptor mRNA and protein levels also the localization of the LDL receptor was 
analyzed in more detail in response to C17orf59 knockdown. For this, a distinction was made 
between LDL-receptor located at the plasma membrane or that inside of the cell.  
To mark exclusively the LDL-receptor at the cell surface, a specific LDL receptor staining was 
established. For this Hela cells were transfected with siRNA against C17orf59 or a negative 
control and cultivated under sterol depleted conditions, which leads to an increase of LDL 
receptor expression compared to control conditions (Goldstein and Brown, 1990). The cells 
were then stained with an antibody specific for the LDL-receptor without using a detergent. 
To avoid uptake of the antibody by endocytosis, the staining was conducted at 4 °C. After 
treatment with a suitable secondary antibody cells were fixed. Imaging of the samples with 
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confocal microscopy revealed a strong reduction of LDL receptor at the plasma membrane 
after knockdown of C17orf59 compared to control treatment (Figure 3.19A). 
To independently validate these results, Hela cells were labeled with DiI-LDL for 30 minutes 
at 4 °C to check how much is bound to the LDL receptor at the plasma membrane. The result 
showed that at reduced levels of C17orf59 the amount of bound DiI-LDL particles were much 
lower than under control conditions (Figure 3.19B). This confirmed the results seen by 
plasma membrane LDL receptor staining (Figure 3.19A) and is well in line with reduced 
uptake of DiI-LDL particles upon C17orf59 knockdown conditions (3.1.3). In order to test 
whether this effect was specific for the LDL receptor, the amount of transferrin receptor, 
which also locates to the plasma membrane, was tested under identical conditions. For this, 
Hela cells were incubated with transferrin coupled to the dye Alexa-568 (Tf-568) for 30 
minutes at 4 °C. Microscopy images revealed also slightly differences of Tf-568 bound at the 
plasma membrane between control and C17orf59 knockdown cells (Figure 3.19B). However, 
this effect was not as obvious as for LDL receptor and DiI-LDL levels. That leads to the 
conclusion, that reduced levels of C17orf59 influence primarily LDL receptor but hardly 
transferrin receptor amounts at the plasma membrane, suggesting that the effects observed 
for C17orf59 knockdown are specific to processes of relevance to cholesterol metabolism. 
 
 
Figure 3.19 LDLR amounts at the plasma membrane after C17orf59 knockdown. (A) Representative 
images of LDLR plasma membrane staining using a specific antibody against the LDLR and a suitable 
secondary antibody labeled with Cy3. (B) Representative images of DiI-LDL and Tf-568 staining and 
their binding to LDL- or transferrin receptor at the plasma membrane. (C) Representative western blot 
and quantifications of LDLR and TfR amounts at the plasma membrane isolated via biotin. (n = 3 
experiments) (scale bar = 10 µm) 
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To further strengthen these data, the amount of LDL receptor as well as transferrin receptor 
at the plasma membrane were additionally measured with an alternative biochemical 
method. For this, cell surface proteins present under control or C17orf59 siRNA treated 
conditions were isolated. Cells were treated with EZ-link sulfo-NHS-SS-Biotin, to label plasma 
membrane proteins. Afterwards cells were lysed and labeled proteins were isolated with 
column bound NeutrAvidin Agarose. Later on, separated plasma membrane proteins were 
checked by western blot analysis. LDL receptor amounts as well as transferrin receptor levels 
were determined and compared between control and C17orf59 knockdown conditions. The 
analysis revealed that LDL receptor, but not transferrin receptor levels were significantly 
reduced after C17orf59 knockdown (Figure 3.19C). This confirmed the previous data from 
immunofluorescence experiments (Figure 3.19A, B). 
In summary immunofluorescence staining’s as well as biochemistry data showed that the 
amount of the LDL receptor at the plasma membrane is reduced after C17orf59 knockdown. 
However, western blot analyses revealed only moderately reduced overall cellular LDL 
receptor levels after knockdown of C17orf59 (Figure 3.18B, C). This lead to the assumption 
that the LDL receptor could be located somewhere else in the cell after C17orf59 knockdown. 
To examine this hypothesis LDL receptor distribution in the whole cell was analyzed by an 
antibody staining. For this, Hela cells were transfected with either control or C17orf59 siRNA 
and cultivated under sterol depleted conditions. After fixation the cells were treated with 
detergent and stained with a specific antibody against the LDL receptor. A suitable secondary 
antibody labeled with a fluorescence tag was used to visualize the LDL-receptor distribution 
by fluorescence microscopy. The received images were analyzed regarding to the mean 
intensity of total cellular staining as well as LDL receptor particle numbers inside the cell. The 
resulted values were compared between control and C17orf59 knockdown conditions. 
Interestingly, these data revealed a higher mean intensity of the antibody signal in cells with 
reduced C17orf59 levels compared to control cells (Figure 3.20A). Also, a higher number of 
LDL receptor particles after C17orf59 knockdown could be measured (Figure 3.20A). In 
addition, intracellular levels of the transferrin receptor were tested using the same method. 
The resulting data indicate that the mean intensity as well as the number of transferrin 
receptor particles inside the cell was also increased in C17orf59 knockdown compared to 
control cells. Although, latter less strongly compared to LDL receptor particle numbers 
(Figure 3.20). 
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In summary, these data show that while overall cellular levels of the LDL receptor after 
C17orf59 knockdown are only moderately reduced, the distribution of the LDL receptor 
within the cell shifted from the plasma membrane towards the cell interior. 
 
 
 
 
 
 
Figure 3.20 Intracellular levels of the LDL- 
and transferrin receptor. (A) Maximum 
projection of representative confocal 
microscopy images of intracellular LDL 
receptor staining using a specific antibody 
against the LDLR and a suitable secondary 
antibody tagged with Cy3. (B) 
Quantification of intracellular LDL-
receptor signal. For determination of the 
mean intensity of the LDLR signal SUM 
projections of confocal microscopy 
images were analyzed. The LDLR particle 
amount was examined on maximum 
projection images. 46 (control siRNA) or 
69 (siC17orf59-1) cells were randomly 
selected and manually marked. Mean 
intensity as well as particle numbers were 
calculated for each cell using ImageJ. (C) 
Maximum projection of representative 
confocal microscopy images of 
intracellular transferrin receptor staining 
using a specific antibody against the TfR 
and a suitable secondary antibody tagged 
with Cy3. (D) Quantification of 
intracellular TfR signal. Calculations were 
done as described in (B). 61 (control 
siRNA) or 56 (siC17orf59-1) cells were 
analyzed. (n = 3 experiments), (scale bar = 
20 µm); (*p < 0.05, ***p < 0.001). 
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Figure 3.21 Different organelle morphologies upon C17orf59 knockdown. Hela cells were transfected 
with either control or siC17orf59-1 siRNA and cultivated in sterol depleted medium (DMEM + 0.5 % 
LDS for 24 h, 1 % HPCD for 45 minutes). After fixation cells were stained with antibodies against 
specific marker proteins including LAMP1 (lysosomes), EEA1 (early endosomes) and GM130 (Golgi 
apparatus). For detection a suitable secondary antibody tagged with Cy3 was used. For F-actin staining 
cells were treated with Phalloidin. Depicted are maximum projections of representative confocal 
images (scale bar = 10 µm). 
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3.2.7 Knockdown of C17orf59 affects organelle morphologies 
In order to investigate the shift of the LDL receptor from the plasma membrane to the cell 
interior after C17orf59 knockdown the integrity of several relevant cellular organelles were 
analyzed under these conditions. For this, Hela cells either transfected with control or 
C17orf59 siRNA were cultivated under sterol depleted conditions. Afterwards several cellular 
organelles were stained using antibodies against organelle specific marker proteins. This 
included LAMP1, a marker protein for lysosomes, EEA1 which stains the early endosomes and 
GM130 a cis-Golgi matrix protein. In addition F-actin was stained with Phalloidin. The 
samples were analyzed by confocal microscopy. The images showed that knockdown of 
C17orf59 indeed affected the morphology of lysosomes as well as the Golgi apparatus, which 
were more scattered compared to control conditions (Figure 3.21). Furthermore, C17orf59 
knockdown moderately affected the actin cytoskeleton, which showed a slightly reduced 
number of filaments in contrast to control conditions (Figure 3.21). 
Because lysosomes, the Golgi apparatus as well as the actin cytoskeleton are all involved in 
vesicle transport within the cell (Bonifacino and Glick, 2004; Robertson et al., 2009) these 
data lead to the assumption that the re-localization of the LDL receptor upon C17orf59 
knockdown could be due to changes in organelle morphology or function. To examine this 
hypothesis, protein transport from the endoplasmic reticulum (ER) via the Golgi apparatus to 
the plasma membrane was analyzed using a temperature sensitive mutant of the vesicular 
stomatis virus glycoprotein (VSVG) coupled with CFP (VSVG-CFP). For this, Hela cells were 
first transfected with either a non-silencing control or a C17orf59 siRNA followed by an 
infection with VSVG-CFP. A temperature shift from 40.5 °C to 32 °C caused the release of the 
virus from the ER via the Golgi apparatus to the plasma membrane. This process was 
analyzed after different time points. A specific antibody was used to stain the virus 
glycoprotein at the plasma membrane, to get an impression how much virus protein is 
transported during a certain time span. These data were compared between control and 
C17orf59 knockdown conditions. The images showed that 30 minutes after release no 
differences between control and reduced C17orf59 levels were visible (Figure 3.22). 
However, 60 minutes after virus release control cells exhibit more virus glycoprotein at the 
plasma membrane than cells reduced for C17orf59 (Figure 3.22) which was obtained by two 
different siRNAs specific for C17orf59. Although these data are only preliminary, similar 
results for C17orf59 were obtained in a large scale analysis using this method (Dr. R. 
Pepperkok, personal communication). 
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In summary, the obtained results lead to the hypothesis, that C17orf59 has a role in LDL-
receptor transport towards or from the plasma membrane. Further experiments will have to 
be performed to understand the molecular details of these findings. 
 
 
Figure 3.22 Comparison of VSVG transport between control and C17orf59 knockdown cells. Cells 
were transfected with control or C17orf59 siRNA and subsequently infected with VSVG-CFP. Cells were 
cultivated at 40.5 °C before they were transferred to 32 °C, which resulted in a release of virus 
glycoprotein from the ER via the Golgi to the plasma membrane. Depicted are maximum projections of 
confocal images showing the virus glycoprotein (VG) amount at the plasma membrane 0, 30 or 60 
minutes after release. VG was made visible by using a specific antibody and a suitable secondary 
antibody coupled with Alexa568 (scale bar = 10 µm). 
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4 DISCUSSION 
4.1 Searching for novel genes involved in cholesterol metabolism 
This work builds on preliminary data sets that aimed at the identification of novel SREBP 
target genes using a combination of genome wide gene expression profiling and in silico 
promoter binding site predictions. The study outcome was validated and the resulting data 
served as basis for further analyses of several promising candidate genes. 
 
4.1.1 Genome wide gene expression profiling 
The availability of the whole human genome sequence since 2004 (International Human 
Genome Sequencing Consortium, 2004) offers the opportunity to identify novel genes 
involved in metabolic processes at a large scale. In combination with microarray analyses it is 
possible to study the expression of almost all genes under certain conditions at the same 
time. This enables for instance the comparison of gene expression patterns between normal 
and diseased cells. As regulation of cholesterol homeostasis depends on the amounts of 
sterols inside a cell (Goldstein and Brown, 1990) it is possible to analyze this metabolism by 
varying this component. Altered mRNA levels are a first indication, that genes are involved in 
the analyzed process. 
In preliminary experiments mRNA levels of 17,848 genes were analyzed in two different cell 
lines after sterol depletion (1.4.1). Under these circumstances the precursor of the SREBP 
transcription factor is activated and regulates the expression of a variety of genes involved in 
cholesterol metabolism. The experiments revealed 189 genes which showed altered mRNA 
levels compared to control conditions. Of these 18 genes could be detected in both cell lines. 
Among these, two genes (ID2, CDC42EP3) were downregulated while the other 16 were 
upregulated after sterol depletion. Most of these genes (14 out of 18) were previously known 
to play a role in cholesterol metabolism. That includes eight genes which are involved in 
cholesterol biosynthesis (ACAT2, ACLY, ACSS2, DHCR7, HMGCR, IDI1, SC4MOL and SQLE). 
Thus, the results show that this important process is activated in both cell types and 
demonstrate that the experimental conditions are suitable to detect genes involved in 
cholesterol homeostasis. The use of two highly distinct cell types, namely human fibroblasts, 
primary cells established from skin biopsy and Hela cells, a cervix carcinoma cell line as well 
as the application of different evaluation strategies could be an explanation why gene 
expression analyses showed only a slight overlap of ~10 %. Additionally, it was conspicuous 
that the up regulation of the LDL receptor, a key protein in cholesterol uptake, was only 
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detectable in fibroblasts but not in Hela cells. Whereas in another study applying the same 
experimental conditions an upregulation of the receptor could be detected also in Hela cells 
(Bartz et al., 2009). This indicates the use of too stringent threshold criteria and would also 
explain the lower number of differentially expressed genes in Hela cells (64 genes) compared 
to fibroblasts (143 genes). 
 
4.1.2 In silico promoter binding site predictions 
Gene expression studies give only a first evidence for genes which are probably involved in a 
certain metabolism. Therefore it is important to confirm this with additional methods. One 
approach for the identification of novel targets of a transcription factor are bioinformatics 
promoter analyses. The promoter regions of interesting genes are scanned for known binding 
sites of the transcription factor. This strategy was also used during the studies preceding this 
work. The intention on the one hand was to identify putative novel SREBP targets and on the 
other hand to reduce potential false positive genes arisen in the gene expression analyses. 
The in silico promoter binding site predictions revealed 99 out of 189 genes as containing one 
or more putative binding motifs for SREBP-1a/ 1c and/ or SREBP-2. Among these, seven of 
twelve cholesterol biosynthesis genes that were differentially regulated in the genome wide 
gene expression profiling, were identified to also contain SREBP binding motifs. Altogether 21 
genes previously linked to cholesterol or fatty acid metabolism could be detected. This 
enrichment of genes encoding cholesterol biosynthesis enzymes among the identified SREBP 
target genes (P = 7.542e-11, compared to all genes of cholesterol biosynthesis), indicates that 
the integrated approach of gene expression studies and promoter binding site predictions is 
suitable for the identification also of novel SREBP target genes. Furthermore, comparison 
with previous studies, dealing with the identification of novel SREBP target genes, while using 
different methods and model organisms, revealed that 26 out of 78 novel putative SREBP 
targets are coinciding. 
Although in silico promoter binding site predictions allow to predict transcription factor 
binding sites over the whole genome and within a short period of time, it has to be taken into 
consideration that the length of a typical transcription factor binding motif ranges between 
only five and ten base pairs. Thus, the false positive rate is likely to be very high. This is 
complicated by the fact that for some transcription factors not only one, but several binding 
motifs are known. A method to reduce false positives is to analyze the identified promoter 
regions for additional binding sites of known transcription cofactors. In the case of SREBP 
these are SP1 and NF-Y. However, the disadvantages mentioned above also apply for these 
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two transcription factors, in particular as they are among the most common in the human 
genome (Bucher, 1990). The promoter analyses revealed that 94 out of 99 genes, including a 
putative SRE element in there promoter region, also contained putative binding motifs for 
SP1 and/ or NF-Y. 
In summary, in silico promoter binding site prediction have some benefits to prioritize target 
genes identified through experimental screening approaches. However, to overcome the 
associated risks experimental strategies to validate the results are essential. 
 
4.1.3 Identification and validation of novel SREBP target genes 
The SREBP family of transcription factors is one of the most important regulators in 
cholesterol homeostasis known today (1.2.3). The availability of the human genome 
sequence and the development of high throughput methods, like microarrays, automatic 
microscopy or next-generation sequencing enable the search for hitherto unknown genes 
regulated by this mechanism at a genome-wide scale. In preceding studies to this work, 
genome wide gene expression profiling was combined with in silico promoter binding site 
predictions to identify novel SREBP target genes (1.4). Others used transgenic SREBP and 
SCAP knockout mice and therewith an in vivo model (Horton et al., 2003) or performed ChIP-
Seq approaches, showing a direct interaction of SREBP with DNA fragments (Seo et al., 2009, 
2011). Beside the mentioned advantages such studies are time consuming, expensive and 
also experimental variability’s caused by their complexity should not be ignored. However, as 
in preceding studies to this work the gene expression analyses were combined only with in 
silico promoter binding site predictions, validation of the resulting data is an inevitable step. 
Ten out of the 99 genes identified as putative novel SREBP target genes were selected for 
further experiments. For this, genes were at first categorized into different groups (Figure 
3.2). Only genes that were upregulated under sterol depletion (67 out of 99), which indicates 
a need under these conditions, were shortlisted. Out of these, only genes which had not 
previously been linked to cholesterol metabolism (49 out of 67) were taken into 
consideration. 20 out of these were also identified by others as putative SREBP target genes 
whereas the remaining 29 were novel. From both groups five genes were chosen for 
validation experiments with care, that selection was as random as possible. Corresponding to 
~20 % of the identified genes showing an upregulation under sterol depleted conditions, but 
were not known to play a role in cholesterol metabolism so far. In a first approach the gene 
expression of the selected candidates was again tested in human fibroblasts and Hela cells 
under sterol depleted conditions. For this, quantitative real-time PCR was applied, which 
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differs from the microarray-based method used in the screening. The resulting data revealed 
a strong tendency for nine out of ten genes to be increased in at least one of the two cell 
lines analyzed, suggesting a high true-positive rate of the microarray experiments. 
Furthermore it was possible to validate five out of ten genes (C17orf59, HES6, SLC2A6, 
TMEM55B and TOB1) in the respective other cell line, that had missed stringent statistical 
criteria in the chip-based experiments, where these genes showed only an upregulation in 
fibroblasts. The same applies for the expression of the LDL receptor, which was used as a 
control. This leads to the conclusion, that the qRT-PCR method is more sensitive and thus an 
adequate approach for validation of the microarray experiments. Although the used sample 
size of ten out of 49 candidates represents a sufficient amount to examine the screening 
data, the analysis of all 49 genes would lead to a more informative result. Such an approach 
should be more feasible in future, using novel strategies, like the NanoString technology. 
The aim of the screening approach was to identify novel SREBP target genes. To test this, the 
five genes which were up regulated in both cell lines after sterol depletion, validated by qRT-
PCR, were chosen for siRNA mediated knockdown experiments in Hela cells. The 
transcriptional activation of four of the five genes tested was suppressed when cellular levels 
of either SREBP-1, SREBP-2 or both were reduced (Figure 3.3) providing direct experimental 
evidence that these genes are truly regulated by the SREBP transcription factors. 
Besides C17ORF59, which was chosen for further analysis also the three other genes (HES6, 
SLC2A6 and TMEM55B) identified in this work turned out as promising candidates. SLC2A6, 
which showed the strongest reduction upon SREBP knockdown, is a member of the family of 
sugar-transport facilitators (Doege et al., 2000; Lisinski et al., 2001), albeit poorly 
characterized yet (Augustin, 2010). Recently SLC2A6 was identified as novel gene with 
potential importance for squamous cell carcinoma (SCC) of the tongue in a genome wide 
gene expression profiling of formalin fixed paraffin embedded patient samples (Rentoft et al., 
2012). Moreover, SLC2A6 was a hit in microarray analyses of peripheral blood cells of 
patients with chronic lymphocytic leukaemia (CLL) associated with trisomy 12 (Porpaczy et 
al., 2009). However a link of SLC2A6 to cholesterol metabolism and/ or SREBP regulation has 
not been described elsewhere. 
TMEM55B, which also showed a reduced gene expression after knockdown of SREBP-2 either 
alone or in combination with SREBP-1, encodes for the protein phosphatidylinositol-4,5-
bisphosphate 4-phosphatase type I. This enzyme catalyzes the hydrolysis of 
phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-5-phosphate (Ungewickell et 
al., 2005). Independently of the results of this work another group observed different 
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expression of this gene in cells treated with statins. In addition, this group identified a 
correlation of TMEM55B levels with variation in HMGCR mRNA levels (Medina and Krauss, 
unpublished data). Additionally, two other studies identified TMEM55B as potential SREBP 
target by chromatin immunoprecipitation (ChIP) (Reed et al., 2008; Rosenbloom et al., 2010). 
These data confirm the results of this work and strongly suggest essential roles of TMEM55B 
in cholesterol metabolism. 
HES6, a member of the Hairy/Enhancer of split family of basic helix-loop-helix transcription 
factors (Pissarra et al., 2000; Vasiliauskas and Stern, 2000) interacts with other transcription 
factors to promote cell differentiation (Bae et al., 2000). HES6 was also identified as putative 
SREBP-2 target gene by a combined analysis of microarray data from transgenic and 
knockout mice (Horton et al., 2003). Very recently, it has been shown that HES6 is involved in 
the regulation of LDL receptor expression (Lee et al., 2012). 
These examples give further evidence that the identified genes indeed play a role in 
cholesterol metabolism. Nonetheless additional experiments are beneficial to confirm these 
results. A replication of the SREBP knockdown experiments in other cell lines, like fibroblasts 
or HuH7 liver cells could strengthen the data. Furthermore, the demonstration of a direct 
interaction of SREBP with the promoter region of the identified genes, using ChiP-Seq or 
Luciferase assays could be informative. Another approach which could support the resulting 
data is the rescue of SREBP knockdown by overexpression of these transcription factors. This 
should restore the expression levels of the candidate genes under sterol depleted conditions, 
whereas overexpression of SREBP alone should lead to an increase of gene expression also 
under control conditions. 
In addition, the results also indicate that it can be reasonable to compare acquired data with 
the results of other studies to further confirm the selection of candidate genes for validation 
experiments. Three of the four genes identified as novel SREBP target genes were identified 
by other large-scale studies as well. 
 
4.1.4 Hela cells as a suitable cell line to study cholesterol metabolism 
Hela cells are easy to grow and RNAi mediated gene knockdown occurs with high efficiency, 
making them an often used model system for large scale screening approaches (Liebel et al., 
2003; Pelkmans et al., 2005; Neumann et al., 2006; Bartz et al., 2009). Among others this has 
been successfully used for identification of novel genes involved in cholesterol metabolism 
(Bartz et al., 2009). Although, Hela cells are not necessarily the first choice for studying 
cholesterol metabolism, it has been shown that important proteins maintaining cholesterol 
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homeostasis are regulated in a sterol dependent manner also in this cell line (Wang et al., 
1994). Moreover, studies revealed the functionality of the LDL receptor in Hela cells(Brown 
and Goldstein, 1976) and knockdown experiments have shown that a reduction of LDL 
receptor expression leads to reduced LDL uptake into Hela cells (Bartz et al., 2009). In this 
work Hela cells were chosen as model organism for the characterization of C17orf59 as 
former studies in the lab identified this gene being regulated under sterol depleted growing 
conditions and indicate a putative function for C17orf59 in cholesterol metabolism in this 
specific cell line (Bartz et al., 2009). Quantitative real-time PCR analyses confirmed the 
upregulation of LDL receptor levels if Hela cells lack sterols (Table 3.1) Additional 
experiments revealed a reduced expression of the LDL receptor under the identical 
conditions when the transcription factor SREBP was downregulated (Figure 3.3). These 
results point toward a general functionality of the cholesterol metabolism in Hela cells. 
Nonetheless, it will be a benefit to confirm results also in other cell lines or model systems, 
reducing the possibility of false positive data and excluding cell line specific effects. 
 
4.2 Characterization of C17orf59 
Most of the genes playing a crucial role in cellular cholesterol homeostasis, like the LDL 
receptor or HMGCR, a key enzyme in the synthesis of cholesterol, are regulated by the SREBP 
family of transcription factors (Yokoyama et al., 1993; Vallett et al., 1996). Binding of SREBPs 
to defined genomic elements leads to an upregulation of expression of these genes if the cell 
lacks sterols. Up to now these two facts are the most common characteristics of genes 
involved in cellular cholesterol metabolism. The very same properties were found for 
C17orf59. Two independent large scale analyses revealed an upregulation of this gene under 
sterol depleted conditions in two different cell lines (1.4.1). These data were confirmed in 
this work by qRT-PCR experiments. In addition two further studies predicted a SREBP binding 
motif in the promoter region of C17orf59 ((Rosenbloom et al., 2010), 1.4.2). This outcome 
was confirmed by siRNA mediated SREBP knockdown experiments leading to a reduced 
regulation of C17orf59 under sterol depleted conditions. The reason why C17orf59 was 
preferred over the other genes for further characterization was that silencing of this gene 
lead to a reduced uptake of LDL into the cell. This was identified via a large scale RNAi 
screening (Bartz et al., 2009) and could be validated and confirmed for three different siRNAs 
in this work. As all these results suggested C17orf59 as very promising novel cholesterol 
regulator this gene was chosen for an in-depth characterization of its implication in lipid 
metabolism. 
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4.2.1 Defining C17orf59 genomic structure 
At the beginning of this work two C17orf59 transcripts were listed in the Ensembl database 
(release 54 – May 2009). At present only one transcript is registered (release 68 – July 2012). 
Due to the fact that this gene consists only of one exon it is unlikely that splicing occurs and 
several splice variants exist. This might be the reason why the database entry was changed. 
Nevertheless, in this work experiments on protein level revealed that both C17orf59 variants 
can be detected although the longer form showed a ~3-fold higher expression than the 
shorter isoform (3.2.2). However, this provides evidence that both variants are existent. 
Many genes in the human genome encode for several protein variants. Besides alternative 
splicing other mechanisms are applied to generate these. This includes alternative promoters 
or more recently recognized, alternative translation start sites (Oyama et al., 2004). The 
latter allows the translation of several protein products from a single mRNA. In general, the 
initiation of translation occurs in eukaryotes by linear scanning of the mRNA. The 40S 
ribosomal subunits are conducted to the 5’-terminal cap structure, scan the mRNA in 5’ to 3’ 
direction, and initiate translation at the first AUG that is recognized (Kozak, 2005; Kochetov, 
2008). Depending on the quality of the nucleotide context, some 40S ribosomal subunits will 
recognize the first AUG and initiate translation, others may skip it, continue scanning and use 
the next downstream AUG as a translation initiation site. This mechanism is called “leaking 
scanning” and results in a N-end truncated protein isoform (Kochetov, 2008). The most 
important nucleotide positions for an optimal context are -3 and +4 referred to the start 
codon. Studies showed that contexts AnnAUGn and GnnAUGG are optimal combinations 
(Pisarev et al., 2006). The first AUG in the C17orf59 sequence complies to this rule 
(AguAUGgag) and seems to have an optimal context for translation initiation. However, the 
closest possible AUG, which constitutes the start of the second C17orf59 variant, fulfills this 
too (GggAUGGat). Thus, in this case a low-level “leaky scanning” maybe occurs. Mostly the 
first AUG is recognized by the 40S ribosomal subunit as translation initiation site, but 
sometimes it will be skipped and the N-terminal truncated isoform will be synthesized. This 
hypothesis is supported by western blot experiments, which revealed a higher protein 
expression of the longer C17orf59 variant compared to the shorter one (3.2.2). 
The generation of several protein isoforms can have a number of reasons. Maybe they differ 
in their subcellular localization, follow various functions or have divergent stabilities. Each of 
these options has to be taken into account in further functional characterization studies. 
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4.2.2 Localization of C17orf59 to the endo-lysosomal system 
One of the essential steps in resolving the function of a novel protein is the determination of 
its subcellular localization. For this, fluorescence microscopy is the most common application. 
In general there are two strategies usable of which both have advantages and disadvantages. 
Proteins can be detected by antibodies which recognize specific peptide sequences. Beside 
the need of a suitable and functional antibody, the disadvantage of this method is that it is 
only applicable in fixed cells. This could lead to the introduction of artifacts occurring from 
fixation or permeabilisation. To overcome this problem it is possible to use fluorescence 
proteins, like GFP, which can be fused to any cDNA of interest. After overexpression the 
localization of the GFP-fusion construct can be analyzed in living cells. The disadvantage of 
this method is the size of the tag (~27 kDa), which can influence the localization of the 
protein of interest, especially when the coupling of GFP leads to masking of an important 
targeting signal. To avoid artifacts arising from the mentioned disadvantages of both 
methods it is useful to analyze the localization of a new protein with both strategies. As a 
suitable antibody against C17orf59 was not available, protein localization was at first 
analyzed using overexpression of C17orf59 linked to a C-terminal EGFP-tag. This revealed an 
accumulation of dots around the nucleus that co-localized with the lysosomal marker protein 
LAMP1 (3.2.4). This was the case for both isoforms, but the highest degree of overlap was 
mainly obvious for the stable transfected shorter form of C17orf59 (C17orf59-T2-EGFP). It 
should be taken into account that endogenous C17orf59 is weakly expressed and that 
overexpression, can lead to artifacts inside the cell. Huge protein amounts can lead to 
accumulations in aggresomes or can induce protein degradation, altering localization is a 
consequence. That C17orf59 could localize indeed in lysosomes was therefore confirmed by a 
microscopy independent approach. Using subcellular fractionation, both transcripts of 
C17orf59 were detected in the same fraction as the lysosomal protein LAMP1 (3.2.4), which 
strengthens the microscopy based results. Nonetheless, it may be useful to conduct further 
experiments to confirm these. One option is to search for possible lysosomal targeting signals 
within the C17orf59 sequence. However, these are not well defined and a first analysis was 
not successful. Another idea would be the inhibition of protein transport from the Golgi 
apparatus to lysosomes with subsequent C17orf59 localization analysis. However, there are 
different ways to transport lysosomal proteins to their destination, some of them are not 
completely understood (Saftig and Klumperman, 2009). 
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4.2.3 Specificity of the C17orf59 knockdown effect on LDL uptake 
Today, one of the most promising strategies for identifying novel genes involved in a certain 
metabolism is the use of siRNA mediated knockdown. The siRNA, which consists of 21 
nucleotides, should thereby bind to a specific mRNA, leading to a reduced expression of the 
corresponding gene. Although this process is highly specific, there is a risk of off-target 
effects. Caused by mismatches between siRNA and target mRNA this can lead to measurable 
phenotypes and therewith to false positive results. Hence, it is important to minimize these 
non-specific effects. One option is to use several siRNAs with different targeting sequences 
against the same gene. This was done for validation of the C17orf59 knockdown effects on 
LDL uptake (3.1.3). In these experiments three siRNAs, with distinct nucleotide sequences 
and from two different companies were used. All of them led to a decreased expression of 
C17orf59, as proven by qRT-PCR experiments as well as to a reduced uptake of LDL, shown by 
the DiI-LDL assay. This gives first evidence that these effects are specific. Nonetheless, to 
demonstrate the specificity of the relevance of a particular protein or a phenotype, rescue 
experiments are desirable. Thereby exogenous nucleic acid is introduced into the cell to 
compensate the lack of protein caused by the siRNA knockdown and thus recover the wild-
type phenotype. For this, a nucleotide sequence encoding for the wild-type protein that is 
resistant to siRNA treatment is required. With the aim to test the specificity of C17orf59 
knockdown effects, several approaches were followed in this study. First, a siRNA binding to 
the untranslated region (UTR) of the gene was used. This allowed the use of the normal wild-
type protein for overexpression, which should not be affected by the siRNA. However, the 
used siRNA did not show an effect on DiI-LDL uptake and was therefore not useful for rescue 
experiments. Besides the possibility of designing a novel, hopefully working siRNA which 
binds at the untranslated region of C17orf59, there is another rescue strategy. For this, a 
siRNA which binds in the coding region of the gene is applied. For restoring the resulting 
effect a DNA construct which is not affected by this siRNAs is used. This could for example be 
a coding sequence from another species, which should have a high similarity to the human 
one or can be produced by the introduction of silent mutation(s). The latter leads to a siRNA 
resistant nucleotide sequence without affecting the wild-type protein structure, thus, the 
mutation has no influence on protein function. In a second approach this strategy was 
applied to check the specificity of the C17orf59 knockdown effect on LDL uptake. Although 
western blot experiments indicated a potential functionality of this approach, an effect on 
the DiI-LDL uptake was not detectable. There was no difference in the cellular DiI-LDL 
amount of cells with a reduced C17orf59 expression and those which contained an 
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overexpressed C17orf59-EGFP construct in addition. Reasons for this could be an 
unphysiologically amount of overexpressed protein. Because C17orf59 shows only a weak 
expression in native state it could be possible that high amounts of the protein lead to 
problems in this complex metabolism, which could also explain why not only knockdown but 
also overexpression of C17orf59 reduced total cellular LDL receptor by ~20 % (3.2.6). To 
exclude this, it would be advisable to use a C17orf59 construct regulated by its native 
promoter. Another point why this approach is not working could be the EGFP-tag, which was 
used to identify cells which are positive for overexpressed C17orf59. However, there is a 
possibility, that this tag disturbs the function of C17orf59. Therefore it would be better to use 
a shorter tag, like HA or FLAG, or resign it completely that however, could lead to detection 
problems. As the C17orf59 antibody is not working for immunofluorescence there is no 
possibility to find out which cells are transfected with the C17orf59 construct. However, a 
significant effect should also be visible without this control. In addition, it should be kept in 
mind, that the mechanism how C17orf59 functions is not yet clear, it could be that further 
factors are important to rescue the effect on DiI-LDL uptake. It is worth noting that the 
rescue experiments were done with the shorter isoform of C17orf59. However, it is possible 
that the longer form of C17orf59 is required to rescue the effect on DiI-LDL uptake. Although, 
preliminary results with the pEGFP-N2-C17orf59-T1 construct showed no effect on DiI-LDL 
uptake after C17orf59 knockdown, the reasons therefore could be the same as mentioned 
before for the shorter construct. 
As it was not possible to restore the knockdown effect of C17orf59 on DiI-LDL uptake with 
the used approaches, further experiments are necessary to resolve the question if this effect 
is indeed specific for C17orf59, although the confirmed results of this study make this very 
likely. 
Beside the rescue, it is equally essential to find out whether the effect on LDL uptake is 
specific or if also other processes are affected by the knockdown of C17orf59. As LDL 
internalization is carried out using the common process of receptor-mediated endocytosis it 
has to be ruled out that C17orf59 knockdown influences the transport of other particles. To 
assess this, transferrin uptake was analyzed at reduced levels of C17orf59. These 
experiments demonstrated that the transferrin uptake was slightly decreased by about 
~20 %. However, this is not as significant as the reduction of the LDL uptake by about ~80 %. 
The analysis of the LDL receptor distribution after C17orf59 knockdown revealed decreased 
amounts at the plasma membrane but in return more LDL receptor in the interior of the cell, 
which has been measured by the fluorescence intensity and LDL receptor particle quantity. 
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This leads to the conclusion, that lower LDL receptor levels at the plasma membrane are 
responsible for the reduced LDL uptake upon knockdown of C17orf59. As control the cellular 
distribution of the transferrin receptor was investigated. Indeed, also for transferrin receptor 
higher fluorescence intensity inside the cell was quantified, however, the number of 
transferrin receptor particles only slightly increased. This is in accordance with the transferrin 
receptor levels at the plasma membrane, for those two distinct detection methods revealed 
only marginal effects after C17orf59 knockdown. Latter explains also the slightly decrease of 
transferrin uptake. Both control approaches, the transferrin uptake as well as the transferrin 
receptor distribution, showed compared to effects on LDL uptake as well as LDL receptor 
distribution only slightly effect after C17orf59 siRNA mediated knockdown. A reason for 
these minor changes could be the scattering of the Golgi apparatus as well as the alteration 
of the actin cytoskeleton at reduced C17orf59 levels. 
These results provide high experimental evidence that the effect of C17orf59 knockdown is 
indeed specific for cellular LDL uptake by influencing the localization of the LDL receptor. 
Furthermore, the specificity indicates that C17orf59 plays a role in processes regarding to the 
LDL- but to a less extent the transferrin receptor. This might help to design further strategies 
for identifying the molecular mechanism how C17orf59 is involved in cholesterol metabolism. 
 
4.2.4 A working model of C17orf59 function 
The results of the present study show that a knockdown of C17orf59 leads to a decreased 
uptake of LDL into the cell. This is with a high likelihood caused by a redistribution of the LDL 
receptor localization from the plasma membrane towards the cell interior. In addition it was 
shown, that reduced levels of C17orf59 lead to a scattering of the Golgi apparatus, altered 
lysosomal structures as well as slight changes of the actin cytoskeleton. 
The current results support the hypothesis that C17orf59 plays a role in the transport of the 
LDL receptor to or from the plasma membrane. Two models might explain this outcome 
(Figure 4.1). On the one hand C17orf59 could be involved in the transport of newly 
synthesized LDL receptor from the Golgi apparatus to the cell surface. This hypothesis is 
confirmed by VSVG-assay experiments, which show that knockdown of C17orf59 delays the 
transport of virus glycoprotein to the plasma membrane (3.2.7). However, currently it is not 
clear, if the transport delay is caused by the scattered Golgi apparatus structure or if latter is 
a consequence of the decreased transport. That’s why, it cannot be excluded that these 
effects are only a reflection of other cellular processes C17orf59 is involved in. On the other 
hand it is possible, that C17orf59 plays a role in the recycling of the LDL receptor from the 
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sorting endosomes via the recycling endosomes back to cell surface. The inhibition of this 
process leads to reduced LDL receptor amounts at the plasma membrane and as a 
consequence to reduced LDL uptake. Hence, the LDL receptor would accumulate inside of the 
cell before degradation occurs. This hypothesis in turn is supported by the endo-lysosomal 
localization of C17orf59. This cellular compartment is directly associated with the recycling 
process. After reaching its total life-span of about ~20 hours the LDL receptor is not further 
recycled but transported into lysosomes for degradation. A deregulation of this process could 
lead to a premature transport of the LDL receptor to lysosomes. Further experiments are 
required to find out if one of these suggested hypotheses is true. 
 
 
 
 
Figure 4.1 Comparison of the physiology of the cell under control and C17orf59 knockdown 
conditions. Experiments in cells with reduced C17orf59 levels showed a decreased uptake of DiI-LDL, 
variances in LDL receptor localization as well as morphological changes, including scattering of the 
Golgi apparatus (B) compared to control conditions (A). At this time it is not known at which 
intracellular compartment the LDL receptor accumulates after C17orf59 knockdown. Therefor two 
hypotheses were developed. On the one hand it is possible that the transport of newly synthesized 
LDL receptor from the Golgi apparatus to the plasma membrane (PM) is impaired (1st hypothesis). This 
would lead to a clustering of the LDL receptor in the Golgi apparatus. On the other hand C17orf59 is 
maybe involved in the recycling process of the LDL receptor from sorting endosomes back to the PM 
(2nd hypothesis), which could result in the accumulation of LDL receptor in the endosomal system. 
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The identification of the intracellular localization of the LDL receptor would give a first 
indication. To figure this out co-localization with several organelle marker proteins should be 
tested. Antibodies against GM130 or TGN46 could be used to stain the Golgi apparatus. A co-
localization of the LDL receptor with these organelle markers would indicate a transport 
problem immediately after protein synthesis and would support therefore the first 
hypothesis. Because there is generally no single, unique marker that can be used to define an 
endocytic organelle, it is more difficult to identify the intracellular LDL receptor localization in 
such a distinct subcellular compartment. However, a co-staining with RAB11 would indicate 
localization in recycling endosomes, whereas an overlap with a LAMP1 staining would lead to 
the conclusion that the LDL receptor localizes to lysosomes. Both results would suggest that 
the LDL receptor recycling is impaired and thus support the second hypothesis. Nevertheless, 
it is necessary to perform additional experiments to clarify the role of C17orf59 in these 
processes. 
Should further studies confirm the direct role of C17orf59 in cholesterol homeostasis, it 
would be possible that mutations within this gene lead to similar effects on cellular LDL 
receptor distribution as it was discovered during this work upon C17orf59 knockdown. This 
would lead to an inefficient LDL uptake from blood which is likely to induce 
hypercholesterolemia. To date seven missense variants in the C17orf59 coding sequence 
could be identified (Exome Variant Server, NHLBI Exome Sequencing Project (ESP), Seattle, 
WA (URL: http://evs.gs.washington.edu/EVS/), 08-2012). However, it remains open whether 
these SNPs are associated with elevated LDL blood levels. Sequencing of C17orf59 in patients 
with hypercholesterolemia or the analysis of already available information from large 
sequencing studies with a relation to cardiovascular disease could provide further evidence 
that this gene plays a role in cholesterol homeostasis. The influence of known missense SNPs 
on LDL uptake could be tested to gain better insights in the molecular mechanism C17orf59 is 
involved in. However, this requires first and foremost a functional rescue approach, which 
despite several attempts failed to be established during this work. 
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5 OUTLOOK 
In this study four novel putative SREBP target genes were identified through to the validation 
of data resulting from a combined genome wide gene expression profiling and in silico 
promoter binding site predictions. Follow up experiments on previously uncharacterized 
C17orf59 revealed that this gene plays a role in cholesterol uptake by influencing the 
localization of the LDL receptor. The results of this work lead to two possible hypotheses 
regarding the underlying molecular mechanism. It is assumed that C17orf59 plays a role 
either in Golgi – plasma membrane transport or is involved in the recycling of the LDL 
receptor. Additional experiments are necessary to analyze this in further detail. To reveal 
which of these two hypotheses is more probable the identification of the intracellular 
localization of the LDL receptor after C17orf59 knockdown is an important step. Analyzing 
the amount of newly synthesized LDL receptor reaching the plasma membrane or 
investigating the timespan between LDL receptor internalization and recycling back to the 
cell surface could give a further hint in which of the two hypothesized pathways C17orf59 is 
maybe involved in. 
As C17orf59 has an influence on cholesterol homeostasis it is conceivable that mutations in 
this gene lead to elevated LDL blood levels. C17orf59 sequence information from patients 
with hypercholesterolemia could give further evidence if variants are directly disease 
causative.  
Should further experiments verify the supposed participation of C17orf59 in cholesterol 
metabolism, knockout mice would be a good model system to study the influence of 
C17orf59 in vivo and therewith gaining more insights on the impact of C17orf59 in the whole 
body. 
Besides C17ORF59 also the other three identified SREBP target genes (HES6, SLC2A6 and 
TMEM55B) should be analyzed in more detail to reveal their function in cholesterol 
metabolism. It is anticipated that in the future further screenings will be conducted which 
will identify novel genes with functional implications for cholesterol metabolism. Novel 
methods are necessary to handle the large number of interesting candidate genes. This 
includes improved bioinformatics tools to minimize false positives as well as approaches 
which allow the simultaneous functional analysis of several genes in parallel. 
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6 MATERIAL AND METHODS 
 
6.1 Material 
 
Table 6.1 Chemicals and Reagents 
Chemical / Reagent Manufacturer 
1,4-Dithiothreitol (DTT) Roth (6908.1) 
10 mM dNTP Mix Fermentas (#R0192) 
10x FastDigest® Buffer Fermentas 
10x Pfu Buffer with MgSO4 Fermentas 
10x Reaction Buffer for SAP Fermentas 
3-(N-morpholino)propanesulfonic acid (MOPS) Sigma (M1254) 
4-Amidinophenylmethanesulfonyl fluoride 
hydrochloride Sigma (A6664) 
5x Reaction Buffer for RT Fermentas (#EP0451) 
6-Aminohexanoic acid Fluka (07260) 
Agar-Agar Roth (5210.1) 
Albumin Fraction V (BSA) Roth (8076.2) 
Amphotericin B PAA Laboratories GmbH (P11-001) 
Ampicillin sodium salt Roth (K029.11) 
Apotransferrin Sigma-Aldrich (T2252) 
Aqua B Braun Melsungen AG (2351744) 
Bacto Yeast Extract BD (212750) 
Benzamidine hydrochloride hydrate Sigma-Aldrich (B6506) 
Bromphenol blue 
(3',3",5',5"-tetrabromophenolsulfonphthalein) Merck (8122) 
Chloramphenicol Roth (3886.2) 
ColorPlus Prestained Protein Ladder New England BioLabs (P7711S) 
cOmplete Mini, EDTA-free Roche (11836170001) 
Cyclohexamide Calbiochem (239764) 
Dimethylsulfoxid Grüssing GmbH (10281) 
DMEM / Ham’s F-12 PAA Laboratories GmbH (E15-813) 
DMEM High Glucose, with L-Glutamine (4.5 g/ l) PAA Laboratories GmbH (E15-810) 
DMEM Low Glucose, with L-Glutamine (1.0 g/ l) PAA Laboratories GmbH (E15-806) 
Dulbecco’s PBS (1x) with Ca & Mg, sterile PAA Laboratories GmbH (H15-001) 
Dulbecco’s PBS (1x) without Ca & Mg, sterile PAA Laboratories GmbH (P15-002) 
ElectroMaxTM DH10BTM cell Life Technologies (18290-015) 
Ethidium Bromide Roth (7870.1) 
Ethylen glycol tetraacetic acid (EGTA) Roth (3054.2) 
Ethylenediaminetetraacetic acid (EDTA) AppliChem (A3553) 
Fetal Bovine Serum Biochrom AG (S0115) 
Ficoll® PM 400 Sigma-Aldrich (F4375) 
Foetal Bovine Serum, delipidized PANTM Biotech GmbH (P30-340) 
GeneRulerTM 1 kb DNA Ladder, 0.5 µg/ µl Fermentas (#SM0311) 
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Gentamycin 418 PAA Laboratories GmbH (P21011) 
Glycerol AppliChem (A2364) 
Glycine AppliChem (A1377) 
HCS CellMaskTM Deep Red stain Invitrogen (H32721) 
Hepes Roth (9105.2) 
Hoechst Sigma-Aldrich (B2261) 
HPCD ((2-Hydroxypropyl)-ß-cyclodextrin) Sigma-Aldrich (C0926) 
Kanamycin sulfate Fluka (60615) 
LE Agarose Biozym Scientific GmbH (840004) 
LipofectamineTM 2000 Reagent (1 mg/ ml) Invitrogen (P/N 52887) 
Low-density lipoprotein from human plasma, 
DiI complex (DiI-LDL), 1 mg/ ml Invitrogen (23482) 
Minimum Essential Medium Eagle  Sigma-Aldrich (M3024) 
NuPAGE MOPS SDS Running Buffer (20x) Invitrogen (NP0001) 
Odyssey Blocking Buffer LI-COR Biosciences (927-40000) 
OligofectamineTM Reagent Invitrogen (P/N 58303) 
OPTI-MEM® I + GlutaMAXTM-I (1x) Gibco (51985-026) 
Orange G ((S)-2-Boc-1,2,3,4-
tetrahydronorharmane-3-carboxylic acid) Fluka (03756) 
Paraformaldehyde Sigma-Aldrich (P6148) 
Penicillin/Streptomycin (100x) PAA Laboratories GmbH (P11-010) 
Pfu DNA polymerase (2.5 u/ µl), 100 u Fermentas (#EP0501) 
Power SYBR® Green PCR Master Mix (2x) Applied Biosystems (P/N 4367659) 
Random Primers ( 3µg/ µl) Invitrogen (P/N 58875) 
RevertAid H Minus RT (200 u/ µl) Fermentas (#EP0451) 
Select Agar Invitrogen (30391-023) 
Shrimp Alkaline Phosphatase (SAP) 1 u/ µl, 500 u Fermentas (#EF0511) 
Sodium bicarbonate Sigma (S5761) 
Sodium chloride Sigma-Aldrich (31434) 
Sodium dodecyl sulfate (SDS) Sigma-Aldrich (L4509) 
Sodium fluoride Aldrich (450022) 
Sodium hydroxide Merck (1.06498.1000) 
Sodium phosphate tribasic dodecahydrate Sigma-Aldrich (71911) 
Sodium pyrophosphate Aldrich (P8010) 
Sodium-ortho-Vanadate Sigma (S6508) 
SpectraTM Multicolor High Range Protein Ladder Termo Scientific (26625) 
Sucrose J.T.Baker (0334) 
T4 DNA Ligase (3 u/ µl), 100 u Promega (M180A) 
T4 DNA Ligase 10x Buffer Promega (C126A) 
Transferrin from human serum Alexa Fluor® 568 
conjugate Invitrogen (T23365) 
Tris Roth (4855.2) 
Triton X-100 Merck (1.08603.1000) 
Tryptone Fluka (T7293) 
Trysin-EDTA (1x) PAA Laboratories GmbH (L11-004) 
Tween® 20 Roth (9127.1) 
λ DNA /HindIII 0.5 µg/ µl Fermentas (#SM0101) 
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Table 6.2 Consumables 
Consumable Manufacturer 
15 ml tubes Greiner bio-one (188271) 
50 ml tubes Greiner bio-one (227261) 
6-well plates Sarstedt (83.1839) 
Absolute QPCR Seal Thermo Scientific (AB-1170) 
Blotting paper Macherey-Nagel (742113) 
Cell Scraper Orange Scientific (5560500) 
Centrifuge Tubes (250 ml) NALEGENE Labware (3121-0250) 
Centrifuge Tubes (30 ml) NALGENE Labware (3119-0030) 
Coverslips (Ø 10 mm) Marienfeld GmbH & Co KG (0111500) 
Cryo tubes Star Lab (E3090-6222) 
Electroporation Cuvette Biozym Scientific GmbH (748010) 
Glass beads, acid washed (425-600 µm) Sigma (G8772) 
Immobilon®-FL (PVDF membrane) Millipore (IPFL00010) 
MicroAmp Fast 96-well Reaction Plate 
(0.1 ml) Applied Biosystems (4346907) 
Microscopy slides Marienfeld GmbH & Co KG (1000200) 
NuPAGE 4-12 % Bis-Tris Gels Life technologies (NP0322BOX) 
Parafilm M STEIN Labortechnik Vertriebsgesellschaft mbH (B3071) 
Pasteur pipettes Chemikalien Lager, University Heidelberg (83386) 
Petridishes (Ø 10 cm) Greiner bio-one 
Petridishes (Ø 15 cm) Nunc (168381) 
Reaction tubes (1.5 ml) STEIN Labortechnik Vertriebsgesellschaft mbH (50802023010001) 
Reaction tubes (2.0 ml) STEIN Labortechnik Vertriebsgesellschaft mbH (508020430100) 
 
 
Table 6.3 Equipment 
Equipment Model Manufacturer 
7500 Fast Real-Time PCR 
System - Applied Biosystems 
Agarose gel chamber EASY-CAST
TM Electrophoresis 
System Model #B1A Owl Scientific, Inc. 
Aluminum plate - Feinmechanik Zentralbereich NF 
Centrifuge (15 and 50 ml 
tubes) Multifuge 3L-R Heraeus 
Centrifuge (cell culture) Z420 M & S Laborgeräte GmbH 
Clean Bench Microflow Biological Safety Cabinet Nunc 
Counting chamber Neubauer improved Marienfeld GmbH & Co KG 
Electroporator E. coli Pulser BIO-RAD 
Foam Pads 8 x 11 cm BIO-RAD 
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Forceps  Fine Science Tools 
Freezer (-20 °C)  Liebherr 
Freezer (-80 °C) BioFreezer Forma Scientific 
Freezing container Cryo 1 °C Freezing Container NALGENE 
Gel chamber XNovex®MiniCell Invitrogen 
Gel documentation system QUANTUM, model 1100 peqlab 
Heating Block ThermoStat plus (1.5 ml) Eppendorf 
Homogenisator RZR 50 Heidolph 
Ice machine MF30 / B-390 Scotsman® 
Incubator, cell culture Steri-Cycle CO2 Incubator Model 381 Thermo Scientific 
Liquid Nitrogen Container Arpege 55 Air Liquide 
Microcentrifuge Biofuge pico Heraeus 
Microwave MWS 2822 Bauknecht 
Mini Gel Holder Cassette - BIO-RAD 
NanoDrop  ND-1000 spectrophotometer Kisker Biotech 
Odyssey Scanner - LI-COR 
PCR machine Mastercycler epgradient S eppendorf 
Photometer Novaspec II Pharmacia Biotech 
Pipettes  Gilson/ Eppendorf 
Plate Centrifuge 2019R NAPCO 
Potter (2 ml) S B.Braun AG 
Power Supply Power PAC 300 BIO-RAD 
Rocking platform GyroTwister Labnet 
Rotor AF 8.50.1 Herolab 
Sample Rotator  neoLab 
Shaker ISF-1-W Kühner Switzerland 
Sonicator W185F Ultrasonics 
Sorvall Centrifuge Sorvall® RC-5B DuPont Instruments 
SORVALL GSA Rotor  DuPont Instruments 
Timer Model No WB388 Oregon Scientific 
Transfer chamber Mini Trans-Blot® Cell BIO-RAD 
Vortexer Top-Mix 11118 Fisher Bioblock Scientific 
Water bath 1086 GFL 
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Table 6.4 siRNAs 
Target RefSeq Name siRNA ID Nucleotide Sequence 5’ 3’ 
C17orf59 NM_017622 
siC17orf59-2 
siC17orf59-3 
siC17orf59-1 
siC17orf59-4 
SI03194457 
43607 
43680 
s226784 
CGAUGCUGUGGACUCCUUAtt 
GCCGUGGACAUGAGCAUCAtt 
GCAUCAAGGGCAUGUACACtt 
GAGUUUUUGUGGAAUUAAAtt 
Control - control SI04026960 UUCUCCGAACGUGUCACGUtt 
SREBF1 NM_004176 siSREBF1-1 s131 AGAAGUUUUGUACAGAGAAtt 
SREBF2 NM_004599 siSREBF2-1 s28 GGAUGAUGCAAAGGUCAAAtt 
TFRC NM_001128148 siTFRC-1 107047 AGCAGUUGGCUGUUGUACCtc 
The control siRNA and siC17orf59-2 were obtained from Qiagen (Hilden, Germany). All others are from 
Applied Biosystems (Darmstadt, Germany). 
 
Table 6.5 Plasmids 
Name Insert Resistance Source 
pEGFP-N2 EGFP Kanamycin Dr. R. Pepperkok, EMBL, Heidelberg, Germany 
pEGFP-N2-C17orf59-T1 C17orf59-T1 Kanamycin this work 
pEGFP-N2-C17orf59-
T1_C957T 
C17orf59-
T1_C957T Kanamycin this work 
pEGFP-N2-C17orf59-T2 C17orf59-T2 Kanamycin this work 
pEGFP-N2-C17orf59-
T2_C555T 
C17orf59-
T2_C555T Kanamycin this work 
pET-28M-SUMO1-
C17orf59-T2 
SUMO1-
C17orf59-T2 Kanamycin 
Susanne Theiß, Human 
Genetics, Heidelberg, Germany 
pET-28M-SUMO1-GFP SUMO1-GFP Kanamycin 
EMBL Heidelberg, Germany, 
Protein Expression & 
Purification Core Facility 
pOTB7-C17orf59 C17orf59-T2 Chlor-amphenicol 
imaGenes GmbH, Berlin, 
Germany 
For further description and the appending vector cards see supplement figures S2, S3 and S4. 
 
Table 6.6 Restriction Enzymes 
Enzyme Specificity 5’ 3’ Digestion Time* inactivation Manufacturer 
DpnI GA(CH3)TC 5 / - 80 °C, 20 min NEB (R0176S) 
FastDigest® 
BamHI GGATCC 5 / 5 80 °C, 5 min 
Fermentas 
(#FD0054) 
FastDigest® BglII AGATCT 20 / 30 No Fermentas (#FD0084) 
FastDigest® EcoRI GAATTC 5 / 20 80 °C, 5 min Fermentas (#FD0274) 
FastDigest® 
HindIII AAGCTT 5 / 20 80 °C, 10 min 
Fermentas 
(#FD0504) 
FastDigest® SalI GTCGAC 5 / 60 65 °C, 10 min Fermentas (#FD0644) 
*based on 1 µl enzyme; first number describes the digestion time in minutes of 1 µg/ 20 µl plasmid 
DNA; second number describes the digestion time in minutes of ~0.2 µg/ 30 µl PCR product. 
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Table 6.7 Primary Antibodies 
Antigen Species Dilution Source 
beta-Actin mouse 1:5,000 (WB) Sigma (A5441) 
C17orf59 rabbit 1:100 (WB) Pineda, see 6.3.8 
EEA1 mouse 1:100 (IF)/ 1:500 (WB) BD Biosciences (610456) 
GM130 mouse 1:400 (IF)/ 1:500 (WB) BD Biosciences (610823) 
LAMP1 mouse 1:200 (IF)/ 1:500 (WB) DSHB, University of Iowa 
LDL receptor mouse rabbit 
1:100 (IF) 
1:250 (WB) 
Progen (61087) 
Cayman (10007665) 
Transferrin 
receptor mouse 1:500 (IF and WB) Invitrogen (13-6800) 
Virus glycoprotein 
(VG) mouse 1:50 (IF) 
Dr. R. Pepperkok (EMBL, 
Heidelberg, Germany) 
IF, immunofluorescence; WB, western blot 
 
Table 6.8 Secondary Antibodies 
Antigen Tag Species Dilution Source 
anti-mouse Alexa488 goat 1:200 (IF) Invitrogen 
anti-mouse CyTM3 goat 1:200 (IF) ZYMED Laboratories 
anti-mouse IRDye® 800CW donkey 1:15,000 (WB) LI-COR Biosciences 
anti-mouse Alexa568 mouse 1:200 (IF) Dr. R. Pepperkok (EMBL, Heidelberg, Germany) 
anti-rabbit IRDye® 680 donkey 1:15,000 (WB) LI-COR Biosciences 
 
Table 6.9 Cloning Primers 
Name Direction Nucleotide Sequence 5’  3’ 
C17orf59_1Mut_fwd_C957T forward GGGCATGTATACCCTGCTGGCGCGCTGCGAGGAG 
C17orf59_1Mut_rev_C957T reverse CTCCTCGCAGCGCGCCAGCAGGGTATACATGCCC 
C17orf59_BC009261_fwd_ 
w/o-ATG_BamHI forward TCATCTGGATCCGATGTTGAGCAGCAGGAGG 
C17orf59_NM017622-fwd-
w/o-ATG_BglII forward TGACAGATCTCAGAGTCGTCTCGGGGG 
C17orf59_rev_STOP_HindIII reverse TCATCTAAGCTTTCACTTGCACAGGGCC 
C17orf59-fwd-ATG forward TGACAGATCTACCATGGATGTTGAGCAGCAGGA 
C17orf59-fwd-w/o-ATG forward TGACAGATCTCAGATGTTGAGCAGCAGGAGG 
C17orf59-fwd-w/o-ATG-SalI forward ACGCGTCGACTGGATGTTGAGCAGCAGGAGG 
C17orf59-NM017622-fwd-
ATG-BglII forward TGACAGATCTACCATGGAGTCGTCTCGGGG 
C17orf59-NM017622-fwd-
w/o-ATG-SalI forward ACGCGTCGACTGGAGTCGTCTCGGGGG 
C17orf59-rev-STOP-EcoRI reverse GCTAGAATTCTCACTTGCACAGGGCC 
C17orf59-rev-STOP-SalI reverse GACTGTCGACTCACTTGCACAGGGCC 
C17orf59-rev-w/o-STOP-SalI reverse GACTGTCGACTCTTGCACAGGGCCTCC 
The primers were obtained from metabion (Martinsried, Germany). 
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Table 6.10 Quantitative real-time PCR Primers 
Gene NCBI Ref Seq. Direction Nucleotide Sequence 5’  3’ Manufacturer 
ANGPTL2 NM_012098 forward reverse 
TCTTCAGGAACTGGGAGACG 
GACCAGTCCTCCATGGTCAC metabion 
C17orf59 NM_017622 forward reverse 
AGCATCAAGGGCATGTACAC 
ACCTCCAGAGTACGTCGGAT 
Eurofins 
MWG Operon 
CPSF1 NM_013291 forward reverse 
TTCTTTGGCAACGTCATGTCC 
CATTCTGCACAAACCCGTCC metabion 
HES6 NM_018645 forward reverse 
GGCCGTGAGGATGAGGAC 
CAGCACTTCGGCGTTCTC metabion 
HMGCR NM_000859 forward reverse 
TAAGCCGAATCCTGTAACTCAG 
GATCAGCTATCCAGCGACTG SIGMA 
KLF6 NM_001160124 forward reverse 
GAGACCGGCTACTTCTCGG 
AGGCTGAAACATAGCAGGGC metabion 
KLF13 NM_015995 forward reverse 
GGAAATCTTCGCACCTCAAG 
GGCAGCTGAACTTCTTCTCG metabion 
LDLR NM_000527 forward reverse 
AGTGTGACCGGGAATATGACT 
CCGCTGTGACACTTGAACTT SIGMA 
MAFB NM_005461 forward reverse 
GACGCAGCTCATTCAGCA 
CCGGAGTTGGCGAGTTTCT metabion 
RPL19 NM_000981 forward reverse 
ACCCCAATGAGACCAATGAAAT 
CAGCCCATCTTTGATGAGCTT SIGMA 
SLC2A6 NM_017585 forward reverse 
ATCCTGACCTGCATCTGACC 
GAGGTCGTTGAGGATCATGG metabion 
SREBF1 NM_004176 forward reverse 
CATCTGTGAGAAGGCCAGTG 
CAAGAAGCAGGTCACACAGG metabion 
SREBF2 NM_004599 forward reverse 
TGCAGCAGGTCAATCATAAAC 
CTAGGTCGATGCCCTTTAGAA   SIGMA 
TMEM55B NM_144568 forward reverse 
AGTGACATCCCAACGGATTG 
TGCGGTCTGTGAACTCTGTC metabion 
TOB1 NM_001243877 forward reverse 
TTCCCAGGAGACGTGTCAAC 
CCCGATCCTTTGTATGGCTTTT Metabion 
 
 
Table 6.11 Sequencing Primers 
Name Direction Nucleotide Sequence 5’  3’ Manufacturer 
pdEYFP_fwd_seq forward CAACGGGACTTTCCAAAATG metabion 
pdEYFP_rev_seq reverse GAACTTCAGGGTCAGCTTGC metabion 
pMT2SM-3xHA_fwd_seq forward CCCAGGTCCAACTGCATAAG metabion 
pMT2SM-3xHA_rev_seq reverse CAGCCTTCACGCTAGGATTG Eurofins MWG Operon 
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Table 6.12 Buffer 
Buffer components 
10x Blotting Buffer 
386 mM 
479 mM 
0.185 % 
Glycine 
Tris 
20 % SDS 
1x Blotting Buffer 
10 % 
20 % 
70 % 
10x Blotting Buffer 
Methanol 
Distilled water 
1x MOPS Running Buffer 5 % 95 % 
20x MOPS Running Buffer 
Distilled water 
1x PBS (pH 7.4) 
137 mM 
2.7 mM 
10 mM 
2 mM 
Sodium chloride 
Potassium chloride 
Disodium hydrogen phosphate 
Potassium dihydrogen phosphate 
4x SDS Sample Buffer 
200 mM 
40 % 
8 % 
0.4 % 
Tris HCl (pH 6.8) 
Glycerol 
SDS 
Bromphenol blue 
Gel Electrophoresis Buffer 10 mM  
Sodiumhydroxide pH 8.5 
with boric acid 
Homogenization Buffer (HB) 
(pH 7.4) 
250 mM 
5 mM 
1 mM 
1 mM 
5 mM 
0.2 mM  
Sucrose 
MOPS 
EDTA 
6-Aminohexanoic acid 
Benzamidine hydrochloride hydrate 
Dithiothreitol 
Lysis buffer (pH 7.5) 
(adapted from (Boyd et al., 2003)) 
10 mM 
5 mM 
5 mM 
50 mM 
50 mM 
1 mM 
5 mM 
2 % 
 
5 mM 
 
Sodium phosphate tribasic dodecahydrate 
Ethylenediaminetetraacetic acid 
Ethylen glycol tetraacetic acid 
Sodium fluoride 
Sodium chloride 
Sodium-ortho-Vanadate 
Sodium-pyro-phosphate 
Triton X-100 
complete Mini cocktail tablet 
4-Amidinophenylmethanesulfonyl fluoride 
hydrochloride (APMSF) 
OrangeG buffer 
20 % 
10 mM 
1 mg/ ml 
Ficoll® PM 400 
Tris/ HCl (pH 7.5) 
OrangeG 
SDM-PCR buffer (10x) 
100 mM 
500 mM 
25 mM 
Tris HCl (pH 8.3) 
Potassium chloride 
Magnesium chloride 
SDS-PAGE Sample Buffer 
62.5 mM 
1 % 
10 % 
Tris HCl, pH 6.8 
SDS 
Glycerol 
TVBE buffer (pH 7.6) 
1 mM 
1 mM 
0.01 % 
Sodium bicarbonate 
Ethylenediaminetetraacetic acid 
Triton X-100 
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Table 6.13 Media 
Medium components 
Imaging Medium – Hepes  30 mM 
Minimum Essential Medium Eagle  
Hepes 
LB medium (pH 7.5) 
1 % 
0.5 % 
1 % 
If required: 1.5 % 
Tryptone 
Yeast Extract 
Sodium Chloride 
Select Agar 
Sterol depletion medium 
 
 
0.5 % 
DMEM Low Glucose, 
with L-Glutamine (1.0 g/ l) 
delipidized Fetal Bovine Serum 
 
 
 
Table 6.14 Solutions 
Solution components 
Mowiol 
2.4 g 
6 g 
6 ml 
12 ml 
Mowiol 4-88 
Glycerol (water-free) 
Dest. Water 
200 mM Tris-HCl pH 8.5 
 
 
6.2 Cell Biology 
 
6.2.1 Cell culture 
 
6.2.1.1 Cell lines and primary cells 
In the present work four cell lines and one type of primary cells were used. All of them 
originate from H. sapiens and grow adherent (Table 6.15). 
 
Table 6.15 Cell lines and primary cells 
Name Cell Type 
a) Cell lines  
HEK293 
Hela, kyoto line 
HuH7 
SH-SY5Y 
embryonic kidney cells 
cervix carcinoma 
hepatocyte derived cellular carcinoma 
neuroblastoma cell line 
b) Primary cells  
Fibroblasts derived from a skin biopsy of a healthy control 
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6.2.1.2 Cultivation of eukaryotic cells 
All cell lines and primary cells used in this work were cultivated at 37 °C, 5 % CO2 and 95 % 
humidity in an incubator. 
Table 6.16 shows the specific culture media compositions used for cultivation of the different 
cell lines. 
When grown to a confluence of 80 – 90 % cells were passaged. For this the old media was 
removed, cells were washed with 5 ml 1x PBS and incubated with 1.5 ml 1x Trysin-EDTA at 
37 °C until the cells started to detach from the culture dish. Then cells were resuspended in 
culture medium and the required amount was transferred into a new 10 cm dish and filled up 
with culture medium to a total volume of 10 ml. 
For experimental proceedings resuspended cells were counted with a Neubauer counting 
chamber and seeded at the required cell number on 6-well plates, 10 or 15 cm dishes 
depending on the experiment. 
 
Table 6.16 Culture media compositions used for cultivation of different cell lines 
Cell line Culture media composition 
HEK293 
DMEM High Glucose, with L-Glutamine (4.5 g/ l) 
10 % FBS 
1 % Penicillin/Streptomycin 
HeLa Kyoto DMEM Low Glucose, with L-Glutamine (1.0 g/ l) 5 % FBS 
HUH7 
DMEM High Glucose, with L-Glutamine (4.5 g/ l) 
10 % FBS 
1 % Penicillin/Streptomycin 
SH-SY5Y 
DMEM / Ham’s F-12 
10 % FBS 
1 % Penicillin/Streptomycin 
Fibroblasts 
DMEM Low Glucose, with L-Glutamine (1.0 g/ l) 
10 % FBS 
1 % Penicillin/Streptomycin 
1 % Amphotericin B 
 
6.2.1.3 Freezing and thawing of cells 
For long-term storage cells were frozen in liquid nitrogen. For this, cells were trypsinized as 
described above (6.2.1.2), transferred into a 50 ml tube and washed with culture media. 
After centrifugation for 5 minutes at 1,000 rpm the supernatant was discarded and the cell 
pellet resuspended in freezing medium, containing 50 % (v/v) DMEM, 40 % (v/v) FBS and 
10 % (v/v) DMSO. The cell suspension was transferred into cryo tubes and slowly cooled 
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down to -80 °C with a rate of 1 °C /minute in an isopropanol filled freezing container. 
Afterwards cells were transferred into liquid nitrogen. 
For re-cultivation, cells were quickly thawed and transferred into a 10 cm dish with pre-
warmed medium. After two passages cells were used for experiments. 
 
6.2.1.4 Stable cell line production 
In this work a Hela Kyoto cell line stably expressing the plasmid pEGFP-N2-C17orf59-T2 was 
used. To generate this, Hela Kyoto cells were transfected with pEGFP-N2-C17orf59-T2 
plasmid DNA as described in 6.2.2.2. When grown to a confluence of 90 – 100 % cells were 
passaged (6.2.1.2). For selection, 0.5 mg/ ml of the antibiotic Gentamycin 418 was added to 
the freshly seeded cells. After an appropriate number of cell passages cells were sorted 
according to their fluorescence intensities by FACS at the Fluorescence Activated Cell 
Scanning/Sorting Facility at ZMBH according to the instructions. Cells without or only with a 
minor EGFP signal were sorted out. Others were further cultivated as described above. The 
sorting was repeated twice. This resulted in a Hela Kyoto cell line with a stable and consistent 
expression of pEGFP-N2-C17orf59-T2, which was used further for overexpression 
experiments. During cultivation cells were treated with 0.5 mg/ ml Gentamycin 418 
periodically. 
 
 
6.2.2 Transfection of cells 
 
6.2.2.1 SiRNA transfection 
The siRNA transfection of eukaryotic cells was carried out with the transfection reagent 
OligofectamineTM. According to the experiment cells were seeded one day before treatment 
in culture medium. In separated reaction tubes the siRNAs and OligofectamineTM were 
diluted in OptiMEM. The amounts depend on the size of the culture dish used (Table 6.17). 
After mixing, an incubation period of five minutes at room temperature followed. Afterwards 
the OligofectamineTM solution was transferred into the siRNA solution, mixed and incubated 
for another 25 minutes at room temperature. The probes were then added dropwise onto 
the cells and mixed with the medium by gentle shaking of the culture dish. Depending on the 
experiment, the transfected cells were incubated 48 to 72 hours prior to analyzing. 
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Table 6.17 Composition of siRNA and OligofectamineTM solutions for siRNA transfection 
Culture dish siRNA [20 µM] + OptiMEM OligofectamineTM + OptiMEM 
6-well dish 3 µl + 177 µl 4 µl + 16 µl 
10 cm dish 6 µl + 714 µl 16 µl + 64 µl 
15 cm dish 16 µl + 704 µl 42 µl + 168 µl 
 
 
6.2.2.2 Plasmid Transfection 
The transfection of cell lines with cDNA plasmids was arranged by the reagent 
LipofectamineTM2000. One day before transfection, cells were seeded for a confluency of 
~70 % in culture medium. In separated reaction tubes cDNA and LipofectamineTM2000 were 
diluted in OptiMEM (Table 6.18), mixed and incubated for five minutes at room temperature. 
Thereafter 100 µl or 250 µl (depending on the culture dish used, see Table 6.18) 
LipofectamineTM2000 solution was added to the cDNA, mixed and incubated for another 20 
minutes at room temperature. During this incubation period the old culture medium was 
exchanged with prewarmed DMEM without FBS. The samples were then added dropwise 
onto the cells and mixed with the medium by gentle shaking of the culture dish. Four hours 
after transfection the medium was exchanged to normal cell culture medium. Depending on 
the experiment, the transfected cells were incubated 12 to 72 hours prior to analyzing. 
 
Table 6.18 Composition of cDNA and LipofectamineTM2000 solutions for cDNA transfection 
Culture dish 0.5 – 2 µg cDNA + OptiMEM LipofectamineTM2000 + OptiMEM 
6-well dish x µl* + 100 µl 2 µl + 100 µl 
10 cm dish x µl* + 250 µl 4 µl + 250 µl 
*has to be calculated for each plasmid separately, depends on the cDNA concentration 
 
6.2.2.3 Combined siRNA and plasmid transfection 
For rescue experiments (3.2.5) a combined transfection with siRNA and plasmid DNA was 
necessary. For this 37,500 Hela cells/ ml were seeded into one well of a 6-well dish, if needed 
onto coverslips. One day after, cells were transfected with siRNA as described in 6.2.2.1. 
48 hours after siRNA treatment cells were transfected with 1 µg plasmid DNA as described in 
6.2.2.2. Differing from the protocol above, four hours after transfection the medium was 
exchanged to DMEM Low Glucose, with L-Glutamine (1.0 g/ l) supplemented with 0.2 % BSA. 
24 hours after plasmid DNA transfection cells were treated according to the experiment. 
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6.2.3 Cell-based assays 
 
6.2.3.1 Immunofluorescence staining of mammalian cells 
Cells were seeded on coverslips and treated according to the experiment. For 
immunofluorescence staining culture medium was removed, cells were washed once in 
1x PBS and fixed in 3 % (w/v) Paraformaldehyde in 1x PBS for 20 minutes at room 
temperature. Afterwards the coverslips were placed with the cell-side facing down on a drop 
of 1x PBS on a Parafilm covered aluminum plate and incubated for 5 minutes. This washing 
step was repeated once. For permeabilization the cells were treated with 0.2 % (v/v) Tween 
in 1x PBS for 5 minutes. Subsequently a 10 minutes incubation step in 3 % (w/v) BSA in 
1x PBS for blocking of unspecific binding sides followed, before the cells were stained with 
the primary antibody (Table 6.7) diluted in 3 % (w/v) BSA in 1x PBS for 1 h. After two washing 
steps in 1x PBS, 5 minutes each, cells were again permeabilized with 0.2 % (v/v) Tween in 
1x PBS for 5 minutes, followed by the treatment with secondary antibody (Table 6.8) diluted 
in 3 % (w/v) BSA in 1x PBS for 30 minutes. After that cells were again washed twice with 
1x PBS for 5 minutes and were then stained for five minutes with the DNA binding dye 
Hoechst (1:1,000) as well as with the HCS CellMaskTM Deep Red stain (1:50,000) diluted in 
1x PBS, to mark the nucleus and the cytosol. The cells were washed again twice in 1x PBS for 
5 minutes and in a last step they were embedded in 5 µl Mowiol on a microscope slide. All 
steps were done at room temperature. 
 
6.2.3.2 Immunofluorescence staining of plasma membrane proteins 
This protocol was adapted from M. C. Willingham (Willingham, 2010) and was used to stain 
the LDL-receptor at the plasma membrane. For all steps during this experiment including PBS 
always sterile PBS supplemented with calcium and magnesium was used. 
Cells were seeded on coverslips and treated according to the experiment. To increase the 
amount of LDL-receptor at the plasma membrane cells were incubated in sterol depleted 
medium (Table 6.13) one day before staining and treated with 1 % HPCD for 45 minutes. 
Prior to staining the old medium was removed and cells were washed once with PBS for five 
minutes at room temperature. All following steps were done at 4 °C to avoid endocytosis of 
bound molecules. Cells were incubated in 2 mg/ ml (w/v) BSA in PBS for five minutes, 
followed by a 30 minutes treatment with the primary antibody (Table 6.7), diluted in 
2 mg/ ml (w/v) BSA in PBS. After five washing steps in 2 mg/ ml (w/v) BSA in PBS cells were 
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incubated with the secondary antibody (Table 6.8), diluted in 2 mg/ ml (w/v) BSA in PBS for 
30 minutes. Cells were then again washed five times in 2 mg/ ml (w/v) BSA in PBS followed 
by a washing step in PBS for five minutes. Afterwards cells were fixed in 3 % (w/v) PFA in PBS 
for 20 minutes, washed three times in PBS for five minutes and stained with Hoechst 
(1:1,000) as well as with the HCS CellMaskTM Deep Red stain (1:50,000) for five minutes. After 
two washing steps with PBS for 5 minutes cells were embedded with 5 µl Mowiol on 
microscopy slides. 
 
 
6.2.3.3 DiI-LDL uptake assay 
DiI-LDL consists of LDL particles mixed with the fluorescent dye DiI. It can be used to monitor 
cellular LDL uptake as an example for receptor-mediated endocytosis. In order to analyze DiI-
LDL uptake, 37,500 Hela cells/ ml were seeded on coverslips and treated according to the 
experiment. To increase the amount of LDL receptor at the plasma membrane and to 
saturate nonspecific LDL-binding sites, cells were incubated in serum-free DMEM Low 
Glucose, with L-Glutamine (1.0 g/ l) supplemented with 0.2 % BSA one day before the 
experiment. To deplete remaining cellular cholesterol the medium was supplemented with 
1 % (w/v) HPCD for 45 minutes at 37 °C. For DiI-LDL labeling old medium was removed and 
cells were washed in Imaging Medium supplemented with Hepes (IM Hepes) and 0.2 % BSA 
for two minutes at 4 °C. To allow binding of DiI-LDL to the LDL-receptor at the plasma 
membrane cells were incubated in 1.25 µg/ ml DiI-LDL diluted in IM Hepes for 30 minutes at 
4 °C. For DiI-LDL uptake cells were heated up to 38 °C for 20 minutes. Afterwards they were 
washed in IM Hepes supplemented with 0.2 % BSA for two minutes at 4 °C. To remove 
remaining DiI-LDL at the plasma membrane cells were treated with IM Hepes pH 3.5 for one 
minute at 4 °C. After that, cells were washed again in IM Hepes supplemented with 0.2 % 
BSA, followed by a washing step in IM Hepes at 4 °C. Thereafter, cells were fixed in 3 % (w/v) 
PFA for 20 minutes, washed in PBS for four minutes and stained with Hoechst (1:1,000) and 
the HCS CellMaskTM Deep Red stain (1:50,000) for four minutes. All these steps were done at 
4 °C. After a final washing step in PBS for four minutes, cells were mounted with 5 µl Mowiol 
on microscopy slides. 
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6.2.3.4 Dynamic DiI-LDL uptake assay 
Analyzing cellular DiI-LDL uptake in a dynamic manner, i.e. at different time points after LDL 
internalization, could give hints at which level this process is influenced by a protein of 
interest. For this, four coverslips were treated in parallel and all experimental steps were 
performed as described above (6.2.3.3) with the exception that DiI-LDL uptake at 38 °C was 
analyzed at zero, ten, 30 and 60 minutes. 
 
6.2.3.5 Transferrin-568 uptake assay 
Transferrin conjugated with Alexa Fluor® 568 can be used to analyze cellular transferrin 
uptake by microscopy. First, 37,500 Hela cells/ ml were seeded on coverslips and treated 
according to the experiment. To saturate nonspecific transferrin-binding sites medium was 
changed one hour before the experiment. For this, cells were washed twice with DMEM Low 
Glucose, with L-Glutamine (1.0 g/ l) and were then incubated in DMEM Low Glucose, with L-
Glutamine (1.0 g/ l) supplemented with 0.2 % BSA. After a short washing step in Imaging 
Medium supplemented with Hepes and 0.2 % BSA at 4 °C for four minutes cells were labeled 
with 100 µg/ ml Tf568 at 4 °C diluted in Imaging Medium supplemented with Hepes and 
0.2 % BSA for 30 minutes. After another washing step with Image Medium supplemented 
with Hepes and 0.2 % BSA at 4 °C for two minutes cells were incubated with 300 µg/ ml 
Apotransferrin diluted in Imaging Medium supplemented with Hepes and 0.2 % BSA for 15 
minutes at 37 °C. Cells were again washed with Image Medium supplemented with Hepes 
and 0.2 % BSA for two minutes at 4 °C before they were fixed in 3 % (w/v) PFA for 20 minutes 
at 4 °C. After a washing step in PBS at 4 °C for four minutes cells were co-stained with 
Hoechst (1:1,000) and the HCS CellMaskTM Deep Red stain (1:50,000) diluted in PBS for four 
minutes at 4 °C. After a final washing step in PBS for four minutes cells were mounted with 
5 µl Mowiol on microscopy slides. 
 
6.2.3.6 Vesicular stomatis virus glyco-protein assay 
A temperature sensitive mutant of the vesicular stomatis virus glycoprotein (VSVG), 
associated with CFP (VSVG-CFP) can be used to monitor and assess the integrity of secretory 
protein transport from the endoplasmic reticulum (ER) via the Golgi apparatus to the plasma 
membrane under different conditions. 
Therefore 37,500 Hela cells/ ml were seeded on coverslips and transfected as described in 
6.2.2.1. 72 hours after transfection cells were infected with VSVG-CFP (provided by Dr. R. 
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Pepperkok, EMBL, Heidelberg, Germany), which was diluted 1:10 in DMEM Low Glucose 
medium. The infection took place in a humid chamber. The dilution depends on the 
efficiency of the virus production and has to be determined for each new virus batch 
individually. The cells were incubated in 50 µl of the dilution/ coverslip for one hour at 37 °C 
and 5 % CO2 in an incubator. Thereafter, cells were washed two times with DMEM Low 
Glucose medium with a subsequent incubation for 20 minutes at 37 °C. After that cells were 
transferred to 40.5 °C and incubated for eight hours. To release the virus, cells were 
transferred for zero, 30 or 60 minutes to 32 °C in a water bath. During this period protein 
synthesis was inhibited by adding 100 µg/ ml cyclohexamide buffered with 25 mM Hepes (pH 
7.5). Afterwards cells were fixed with 3 % paraformaldehyde for 20 minutes at room 
temperature. This was followed by a co-staining of the cells. For this, cells were treated with 
30 mM glycine (pH 7.5) diluted in PBS for five minutes at room temperature. After three 
washing steps for four minutes in PBS cells were incubated with the primary mouse antibody 
anti-VG diluted 1:50 in PBS. Cells were washed again three times in PBS for four minutes 
before they were incubated with the secondary antibody Alexa-568 anti-mouse diluted 1:200 
in PBS. After three washing steps for four minutes in PBS cell were stained for five minutes 
with Hoechst (1:1,000). Finally cells were washed two times for four minutes in PBS and were 
then embedded with 5 µl Mowiol on microscopy slides. 
 
6.2.4 Microscopy 
 
6.2.4.1 Automated fluorescence microscopy 
Automated fluorescence microscopy was used to acquire images of DiI-LDL (6.2.3.3 and 
6.2.3.4) as well as Transferrin-568 (6.2.3.5) uptake experiments. This kind of microscopy 
technique was performed at the Advanced Light Microscopy Facility (ALMF, EMBL, 
Heidelberg, Germany), using the ScanR system (model IX81) with an UPlanSApo 10x / NA 0.4 
objective from Olympus (Shinjuku, Tokyo, Japan). As light source a MT20 xenon lamp was 
used. The images were acquired automatically and were captured with an Olympus DBH1 
camera using the Scan^R Acquisition software version 2.1.0.15 TS (Olympus). First the 
microscopy stage was manually calibrated. Then the focal plane was determined by an 
object-based autofocus which was adjusted for the Hoechst channel. For this, a coarse 
autofocus consisting of 30 steps with a step width of 5.33 µm and a fine autofocus 
comprising 17 steps with a step width of 0.82 µm was used. The resulting focal plane was 
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used to acquire images of the Hoechst, Cy3 (DiI-LDL and Transferrin-568), Cy5 (DeepRed) and 
if required the GFP-channel. The exposure times were adjusted for each experiment 
separately. Per coverslip 25 images were acquired. The images were automatically saved as 
12-bit tiff-files and later on analyzed with the software DetecTiff (6.2.4.4). 
 
6.2.4.2 Confocal laser scanning microscopy 
Confocal laser scanning microscopy was done at the Advanced Light Microscopy Facility 
(ALMF, EMBL, Heidelberg, Germany), using a UltraVIEW VoX microscope (PerkinElmer, 
Waltham, Massachusetts, USA) with a 63x ZeissPlan-Apochromat oil-immersion objective 
with a numeric aperture (NA) of 1.4. Stacks of 20 images, covering the full vertical extend of 
the sample, were captured with a Hamamatsu EMCCD C9100-50 camera using the Volocity® 
3D Image Analysis Software (PerkinElmer, Waltham, Massachusetts, USA). The images were 
exported as tiff-files and analyzed with the software ImageJ (6.2.4.3). 
 
6.2.4.3 Image analysis with ImageJ 
ImageJ (http://rsbweb.nih.gov/ij/) is a Java-based open-source image processing software 
developed at the National Institutes of Health (NIH, Bethesda, Maryland, USA). 
During this work the software version 1.45s was used to quantify protein amounts resulting 
from western blot experiments, to handle the images originating from confocal laser 
scanning microscopy and to analyze the intracellular localization of the LDL-receptor as well 
as of the transferrin receptor. 
a) Quantification of Protein Expression 
Western blot experiments were done with the Odyssey system (6.3.4). For comparing the 
protein amount between different experimental conditions the quantity of the protein of 
interest was normalized to respective beta-Actin levels. For this, the colored TIF-file resulting 
as output of the Odyssey V3.0 Application Software was converted into an 8-bit image, the 
background was subtracted, the protein bands were framed individually using the ROI mask 
function and the integrated density was measured. Calculations were done with Microsoft 
Excel (Microsoft Corporation, Redmond, Washington, USA). 
b) Confocal image processing 
Confocal z-stacks containing 20 images were recorded on the UltraVIEW VoX microscope 
using the Volocity® 3D Image Analysis Software (6.2.4.2) and were exported as TIF-files. The 
plugin “Substack Select” was used to make substacks of each single fluorescence channel. 
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The stack was then combined to one single image by applying the z-projection showing the 
maximum intensity of each pixel. If necessary brightness and contrast of the image were 
adjusted. By merging the different fluorescence channels an RGB image was generated. 
c) Analyzing intracellular particles 
The aim was to identify the number as well as the mean intensity of LDL- and transferrin 
receptor particles inside the cell to compare them between control and C17orf59 knockdown 
conditions (3.2.6). For this, confocal images were recorded and handled as described above 
in section b. For analyzing the number of particles the z-projection showing the maximum 
intensity of each pixel was used. For intensity analysis of the particles the SUM projection 
was preferred. After background determination and subtraction the outline of each cell was 
defined manually using the ROI (region-of-interest) mask function. To discriminate between 
subcellular objects and non-labeled structures on the image a threshold was manually 
adjusted. To ensure comparability, for each image the same values were applied. The output 
image was used to identify cellular particles for measuring - in combination with the ROI 
masks - the number and total area of particles inside the cell as well as their mean intensity 
referred to the original image. In addition the area of the cell was determined. Further 
calculations were done with Microsoft Excel (Microsoft Corporation, Redmond, Washington, 
USA). 
 
6.2.4.4 Automated image analysis with DetecTiff 
DetecTiff© is a LabView-based automated image analysis software (Gilbert et al., 2009) which 
was used in this work to analyze the DiI-LDL (6.2.3.3 and 6.2.3.4) as well as the transferrin-
568 (6.2.3.5) uptake into cells to compare these data between control and C17orf59 
knockdown conditions. For this purpose images acquired by automated fluorescence 
microscopy (6.2.4.1) were visually checked for adequate total plane, cell density and viability. 
If they did not meet the criteria they were discarded and not taken into account during 
analysis. DetecTiff settings that were used for image analyses are listed in table 6.19. The 
measured parameters were automatically saved as txt-file. For further analysis the 
MetaQuant.txt file which sums up the information for each image of one analysis run was 
used. For each experiment and condition the mean of all “median endos” values, which 
comprises the median of the background-subtracted integrated pixel intensity of each cell in 
one image, was calculated and normalized to control conditions. All calculations were done 
in Microsoft Excel (Microsoft Corporation, Redmond, Washington, USA). 
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Table 6.19 DetecTiff settings 
Assay Cell Mask Readout 
 Threshold IRF* Area size Threshold IRF* Area size 
DiI-LDL uptake 200 5 300-1200 200 20 1-50 
Tf-568 uptake 255 20 200-1200 255 3 1-100 
*IRF, intensity reduction factor 
 
 
 
6.3 Biochemistry 
 
6.3.1 Cell Lysis for Protein Quantification 
Hela cells were seeded in 6-well plates or 10-cm dishes, depending on the required protein 
amount, and treated according to the experiment. 
For cell lysis the old medium was removed, cells were washed in PBS and 100 µl (6-well plate) 
or 200 µl (10 cm dishes) lysis buffer were added. The cells were scraped and collected in 
1.5 ml reaction tubes. In addition the samples were treated with two tips of a spatula glass 
beads (425-600 µm) and mixed for 30 seconds. The supernatant was then transferred into a 
new 1.5 ml reaction tube. 
Thereafter, the protein amount of the samples was determined (6.3.2) or they were stored 
until usage at -20 °C. 
 
6.3.2 Quantitation of total protein amount 
To make results from different samples in western blot experiments comparable, the same 
protein amount needs to be loaded on the gel (6.3.3). For this, the protein concentration was 
determined with the Pierce® BCA Protein Assay Kit (Thermo Scientific (23225)) according to 
the instructions of the manufacturer. As measurements were carried out with the NanoDrop 
spectrophotometer only 200 µl working reagent were used per sample, which were 
incubated for 30 minutes at 37 °C. After down cooling to room temperature, BSA standards 
as well as the samples were measured with the “Protein BCA” program at the NanoDrop 
spectrophotometer. 
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6.3.3 SDS Polyacrylamide Gel Electrophoresis 
SDS polyacrylamide gel electrophoresis was used to separate proteins after cell lysis 
according to their size to analyze them later on by western blot (6.3.4). 
In most cases the aim was to compare protein amounts after different growing conditions or 
treatment with siRNAs. To make sure to load the same protein amount of different samples 
onto the gel the protein concentration of the cell lysate was determined with the Pierce® 
BCA Protein Assay Kit (6.3.2). A protein amount between 10 to 20 µg was loaded onto the 
gel. For this, the samples were diluted in water according to their concentration and 
supplemented with 4x SDS sample buffer as well as 9 % 1 M Dithiothreitol (DTT). 
The run was performed with the XNovex®MiniCell system from Invitrogen. For protein 
separation NuPAGE 4-12 % Bis-Tris Gels were put into the Gel chamber filled with 1x MOPS 
SDS Running buffer. Before loading the samples were heated up to 40 °C for five minutes. 
Depending on the size of the analyzed proteins 4 µl of different protein marker were loaded 
in addition to the protein samples onto the gel. ColorPlus Prestained Protein Ladder was 
used to estimate protein sizes between 10 and 230 kDa, while SpectraTM Multicolor High 
Range Protein Ladder could indicate molecular weights between 40 to 300 kDa. The 
electrophoresis was performed at 120 V for ~80 minutes until the protein front reached the 
lower end of the gel. 
 
6.3.4 Western Blot 
The Western Blot method was used to transfer proteins which had previously been 
separated by SDS polyacrylamide gel electrophoresis (6.3.3) onto a membrane to detect 
them afterwards by specific antibodies. 
The blotting was performed with the Mini Trans-Blot® Cell system from BIO-RAD. The protein 
transfer occurred in a Mini Gel Holder Cassette where the gel and the membrane were 
embedded into a sandwich with the following composition (from the bottom to the top of 
the blotting clamp):  
1. buffer-soaked foam pads 
2. two buffer-soaked sheets of filter paper 
3. gel 
4. PVDF membrane (activated in methanol) 
5. two buffer-soaked sheets of filter paper 
6. buffer-soaked foam pads 
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The Mini Gel Holder Cassette was then put into a transfer chamber, containing 1x Blotting 
Buffer, with the membrane side facing the positive pole. To avoid heating up of the buffer 
during blotting an ice pack was also put into the transfer chamber. The transfer was 
performed at 120 V for 90 minutes. The ice pack was changed after 45 minutes. 
 
6.3.5 Analysis of the western blot 
For protein detection on the western blot membrane the Odyssey system was used. After 
blotting the membrane was blocked in Odyssey Blocking Buffer diluted 1:1 in PBS for one 
hour at room temperature on a shaker to eliminate unspecific binding sites. Subsequently 
the membrane was incubated over night at 4 °C with the primary antibody (Table 6.7) which 
was diluted in Odyssey Blocking Buffer, PBS (1:1) and 0.2 % Tween-20. Afterwards the 
membrane was washed four times for five minutes each at room temperature in PBS 
supplemented with 0.1 % Tween-20 on a shaker. The membrane was then covered with 
fluorescent-labeled secondary antibody (Table 6.8) which was diluted in Odyssey Blocking 
Buffer, PBS (1:1) with 0.2 % Tween-20 for one hour at room temperature by gentle shaking. 
The membrane was again washed four times for five minutes each at room temperature in 
PBS supplemented with 0.1 % Tween-20 on a shaker before it was rinsed with PBS to remove 
residual Tween-20. For detection of the fluorescence signal the membrane was scanned on 
the Odyssey Scanner using the Odyssey V3.0 Application Software. 
For comparison of the protein amount under different conditions the protein of interest was 
normalized to the respective beta-Actin levels, which was always detected in the same lane 
on the identical gel. The quantification was done with the software ImageJ (6.2.4.3). 
 
6.3.6 Cell surface protein isolation 
With the aim to quantify the amount of LDL-receptor and transferrin-receptor at the plasma 
membrane under control compared to C17orf59 knockdown conditions, cell surface proteins 
were isolated via biotinylation. 
Because a high amount of cells was needed for this experiment two 15 cm dishes with 
1,500,000 Hela cells per dish were seeded per condition. One day after seeding cells were 
transfected with siRNA for 72 hours as described in section 6.2.2.1. The isolation of cell 
surface proteins was carried out with the Pierce® Cell Surface Protein Isolation Kit (Thermo 
Scientific (89881)) according to the protocol of the manufacturer. 
  MATERIAL AND METHODS 
 
 
81 
As protease inhibitor the complete Mini cocktail tablets were used according to the protocol 
of the manufacturer. After cell lysis the protein amount of the supernatant was determined 
with the Pierce® BCA Protein Assay Kit (6.3.2) to load a comparable amount of both samples 
onto the columns. After protein elution the samples were stored at -20 °C before they were 
analyzed with SDS Polyacrylamide Gel Electrophoresis (6.3.3) and western blot (6.3.4). 
 
6.3.7 Subcellular fractionation 
Subcellular fractionation was used to enrich organelles from whole cell lysate to determine 
the localization of the endogenous C17orf59 protein. A short overview of this method is 
depicted in figure 6.1. 
Because a huge amount of raw material is needed Hela cells were grown on ten 10-cm-dishes 
in normal cell culture medium. After reaching a confluence of about 90 % the growth 
medium was aspirated and cells were washed twice with 5 ml ice-cold PBS. For cell lysis 2 ml 
ice-cold 1x homogenization buffer (HB) were added to the culture dish, cells were scraped 
and the cell suspensions from all 10 cm-dishes were combined in a 50 ml reaction tube. After 
centrifugation at 260 g at 4 °C for five minutes the supernatant was aspirated. The pellet was 
resuspended in 1.5 ml HB. The suspension was put in a 2 ml potter on ice and was 
homogenized with one stroke consisting of 30 seconds down and 30 seconds up movement 
of the pestle at 1,000 rpm. A 50 µl aliquot of the homogenized suspension (fraction A) was 
collected as an input control. The rest was transferred into a 2 ml tube and centrifuged at 
1,950 g at 4 °C for ten minutes. The resulting pellet (fraction B), consisting of membrane 
fragments, mitochondria, some lysosomes and peroxisomes, was resuspended in 500 µl HB 
and stored on ice. The supernatant (including lysosomes, microsomes and peroxisomes) 
(fraction C) was collected in a 15 ml  tube and centrifuged at 37,000 g for 20 minutes at 4 °C. 
The resulting supernatant (containing microsomes and the soluble fraction) (fraction E) was 
transferred into a 2 ml reaction tube and stored on ice. The pellet (containing lysosomes, 
microsomes and peroxisomes) (fraction D) was first dried and afterwards carefully 
resuspended in 200 µl HB using a partly fused pasteur pipette. 
The protein amount of each fraction was determined by using the Pierce® BCA Protein Assay 
Kit (6.3.2). For this the samples were diluted in TVBE buffer which leads to a breakup of the 
organelles and ensures access to the proteins for correct measurement. 
The single fractions were stored at -20 °C until they were used for western blot analysis. 
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Figure 6.1 Overview about the subcellular fractionation method. See text for details. 
 
6.3.8 C17orf59 antibody production 
Because until now there is no commercial antibody against C17orf59 available we initiated 
the production of a polyclonal antibody in rabbit by the company Pineda (Berlin, Germany). 
Because for antibody production purified protein is needed C17orf59-T2 was cloned into the 
vector pET-28M-SUMO1-GFP (Table 6.5, done by Susanne Theiß). Protein expression in E. coli 
and the purification was done by the Protein Expression and Purification Core Facility at 
EMBL (Heidelberg, Germany). 1 mg purified C17orf59 dissolved in PBS were sent to the 
company Pineda (Berlin, Germany). The antibody was produced in two rabbits and occurred 
in accordance with the basis immunization protocol of the company. After 190 immunization 
days the serum of one of the two animals contained an antibody which allowed for detection 
of endogenous C17orf59 protein in western blot analysis. This serum was used at a dilution 
of 1:100 in western blot experiments against C17orf59 during this work. 
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6.4 Molecular Biology 
 
6.4.1 Isolation of cellular RNA 
For analyzing gene expression after certain treatments total RNA was isolated from the 
whole cell lysate. For this, cells were seeded and treated according to the experiment. Before 
cell lysis old medium was removed and cells were washed once with PBS. The isolation of 
cellular RNA was carried out with the InviTrap Spin Cell RNA Kit (Invitek 1061100200) 
according to the instructions of the manufacturer (handbook pages 16/17, Protocol 1). The 
isolated RNA was immediately put on ice and the concentration was measured with a 
NanoDrop ND-1000 spectrophotometer. The samples were directly reversely transcribed into 
complementary DNA (cDNA) (6.4.2) or stored at -80 °C. 
 
6.4.2 Reverse transcription of RNA to cDNA 
With the aim to analyze gene expression via quantitative real time PCR, isolated RNA (6.4.1) 
was translated into cDNA. This was performed with the RevertAid H Minus Kit (Thermo 
EP0452). 500 – 2,000 ng RNA was diluted in H2O (Aqua) to an endvolume of 12 µl, 1 µl 
random primers (0.2 µg/ µl) was added and the solution was incubated for five minutes at 
70 °C. After down cooling to room temperature 4 µl 5x Reaction Buffer for RT and 2 µl 2 mM 
dNTP-mix were added. After five minutes at room temperature the samples were 
supplemented with 1 µl RevertAid H Minus RT (200 u/ µl) and incubated for one hour at 
42 °C. The enzymatic reaction was stopped by heating up the reaction mix to 70 °C for five 
minutes. After down cooling to room temperature, 80 µl H2O (Aqua) were added to an 
endvolume of 100 µl. The samples were directly used for quantitative real time PCR (6.4.3) or 
stored at -20 °C. 
 
6.4.3 Quantitative Real Time PCR 
The quantitative real time PCR was used to analyze gene expression under different 
experimental conditions. For this, RNA of cultivated cells was isolated (6.4.1) and translated 
into cDNA (6.4.2). As a reference gene the ribosomal protein L19 (RPL19) was used. 
Quantitative real time PCR was carried out in a MicroAmp Fast 96-well Reaction Plate. Each 
reaction was done in triplicates. For one reaction 1 µl cDNA was pipetted with 7.8 µl H2O and 
0.6 µl (10 pmol/ µl) forward as well as reverse primer for the gene of interest (see 6.9) into 
the reaction plate. Afterwards 10 µl of Power SYBR® Green PCR Master Mix (2x) were added, 
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the plate was sealed with an Absolute QPCR Seal and centrifuged at 1,000 rpm for one 
minute to remove air bubbles from the bottom of the plate. The qRT-PCR was performed 
with a 7500 Fast Real-Time PCR System using the 7500 Fast System SDS Software. The PCR 
program consisted of one initial two minutes step at 50 °C, one ten minutes denaturing step 
at 95 °C and 40 cycles consisting of 15 seconds at 95 °C and one minute at 65°C. After each 
cycle the intensity of the fluorescence signal was detected. In addition at the end of the PCR 
reaction a dissociation stage consisting of 15 seconds at 95 °C, one minute at 60 °C and 15 
seconds at 95 °C was added to test the primer reactivity. 
 
6.4.4 Quantitative Real Time PCR data analysis 
For quantification of the real time PCR results the ΔΔCT method was used. For this, CT values 
were determined. This threshold cycle (CT) is the PCR cycle where defined fluorescence 
intensity is obtained. The expression of the gene of interest was analyzed relative to the 
housekeeping gene RPL19. First of all the mean CT values of triplicates of the candidate genes 
as well as of the control gene were calculated. Out of this the ΔCT values at control as well as 
under modified conditions were calculated: 
ΔCT (control) = MeanRPL19 (control) – Meancandidate gene (control) 
ΔCT (modified) = MeanRPL19 (modified) – Meancandidate gene (modified) 
Subsequently the ΔΔCT value was calculated: 
ΔΔCT = ΔCT (control) - ΔCT (modified) 
Out of it the 2-ΔΔCT value was assessed. This resulted in a reference value of 1 with the 
candidate gene value relative to 1. That means a value of 0.5 indicates a down regulation of 
50 % whereas a value of 2 displays a 2fold up regulation of the candidate gene at modified 
compared to control conditions. 
 
6.4.5 Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used for specific amplification of DNA molecules. 
The PCR reaction mix included 50 – 100 ng DNA template, 5 µl 10x Pfu Buffer with MgSO4, 
1 µl 10 mM dNTPs, 1 µl of the appropriate forward as well as reverse primers (10 pmol/ µl) 
(table 6.10) and 1.25 u Pfu polymerase. The mix was filled up with water to a final volume of 
50 µl. The PCR program consisted of one initial three minutes denaturing step at 95 °C, 35 
cycles consisting of 30 seconds at 95 °C, 30 seconds at 57 °C and two minutes at 72 °C, and a 
final elongation step for five minutes at 72 °C. 
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6.4.6 Site-Directed-Mutagenesis 
For rescue experiments site-directed-mutagenesis was used to introduce a mutation into the 
C17orf59 sequence. For this, a polymerase chain reaction with a total volume of 50 µl was 
prepared. As template 20 – 50 ng of the plasmid DNA pEGFP-N2-C17orf59-T1 or pEGFP-N2-
C17orf59-T2 (Table 6.5) was used. In addition 5 µl SDM-PCR buffer (10x), 1 µl 10 mM dNTPs, 
1 µl of the appropriate forward as well as reverse primers (10 pmol/ µl) (table 6.10) and 2.5 u 
Pfu polymerase were added. The mix was filled up with water to the endvolume. The PCR 
program consisted of one initial 30 seconds denaturing step at 95 °C, 16 cycles consisting of 
one minute at 95 °C, one minute at 55 °C and 12 minutes and 30 seconds at 68 °C, and a final 
elongation step for ten minutes at 68 °C. After analysis of the PCR product on an agarose gel 
(6.4.7.1) the sample was treated with DpnI (6.4.9.1) and transformed into E. coli (6.4.10.1). 
 
 
6.4.7 Analysis of DNA molecules 
 
6.4.7.1 Agarose gel electrophoresis 
The agarose gel electrophoresis was used for analytical and preparative separation and 
identification of DNA molecules. For this, 1 % agarose was dissolved in gel electrophoresis 
buffer by boiling in a microwave, 5 µl ethidium bromide (5 mg/ ml) were added and the 
solution was poured into a agarose gel chamber. A comb was put into the gel to create the 
slots for the samples. For loading the gel OrangeG sample buffer (4x) and water were added 
to the DNA probes. Depending on the size of the analyzed DNA fragments, different DNA 
markers were loaded in addition to the DNA samples onto the gel. GeneRuler 1 kb DNA 
Ladder was used to estimate DNA sizes between 250 and 10,000 bp, while the λ DNA /HindIII 
marker allowed for a estimation of sizes between 125 bp and 23,000 bp. Electrophoresis was 
conducted at 120 V for 40 minutes. Afterwards the DNA ethidium bromide complex was 
analyzed and imaged with the gel documentation system using UV-light. 
 
6.4.7.2 Quantitation of the DNA amount 
The concentration of DNA solutions was determined with the NanoDrop Nucleic Acid 
program by measurement of the absorption at 260 nm. 
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6.4.7.3 DNA sequence analysis 
Sequencing was used to check the accuracy of a DNA sequence. It was performed by the 
GATC Biotech AG (Konstanz, Germany). For this, the DNA samples as well as appropriate 
sequencing primers (Table 6.11) were sent to the company, according to their instructions. 
The received sequences were then compared to annotated ones to examine the correctness.  
 
6.4.8 Purification of DNA molecules from solutions and agarose Gels 
The purification of DNA molecules from solutions was carried out with the QIAquick® PCR 
Purification Kit (Qiagen, Hilden, Germany, 28104) according to the instructions of the 
manufacturer. 
The purification of DNA molecules from agarose gels was carried out with the GeneJETTM Gel 
Extraction Kit (Fermentas GmbH, St. Leon-Rot, Germany, K0691) according to the instructions 
of the manufacturer. 
 
6.4.9 Enzymatic modification of DNA molecules 
 
6.4.9.1 Restriction enzyme digestion of DNA molecules 
The restriction enzyme digestion of DNA molecules was used for preparative as well as for 
analytical experiments. 
The vector digestion reaction contained 1 µg DNA, 1 µl of the appropriate restriction 
enzyme(s) (Table 6.5) and 2 µl 10x FastDigest® Buffer. The mix was filled up with water to a 
final volume of 20 µl. The reaction mixture was incubated at 37 °C for ten minutes. 
Thereafter, the enzymes were inactivated (if possible) by heating up to 80 °C for ten minutes. 
The reaction for PCR product digestion contained of 0.2 µg DNA, 1 µl of the appropriate 
restriction enzyme(s) (Table 6.6) and 3 µl 10x FastDigest® Buffer. The mix was filled up with 
water to a final volume of 30 µl. The reaction mixture was incubated at 37 °C for 60 minutes. 
Then, the enzymes were inactivated as mentioned above. 
After site-directed-mutagenesis (6.4.6) the template plasmid DNA was destroyed by a 
restriction digestion with DpnI. For this, 1 µl of the enzyme was directly pipetted into the 
completed PCR mix and incubated for one hour at 37 °C. 
For control analysis of plasmid preparations (6.4.10.2) the volume of the reaction amounted 
to 20 µl, contained 2 µl DNA as well as the components mentioned above. The reaction took 
place at 37 °C for ten minutes. 
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6.4.9.2 Dephosphorylation of DNA molecules 
With the aim to avoid a renewed connection of the restriction enzyme digested DNA, the 
plasmid was dephosphorylated at the 5’-end. Therefor 1 u Shrimp Alkaline Phosphatase (SAP) 
was used and directly after the digestion reaction (6.4.9.1) pipetted into the reaction 
mixture. In addition 10x Reaction Buffer for SAP were added and the mix was incubated for 
60 minutes at 37 °C. Afterwards the inactivation of the enzyme occurred at 80 °C for 20 
minutes. 
 
6.4.9.3 Ligation of DNA fragments 
With the aim to combine linear DNA molecules the neighboring 3’-hydroxyl- and 5’-
phosphate groups were connected by using a T4 DNA Ligase. For this, the reaction mixture 
contained the insert and the plasmid in a proportion of 3:1, 2 µl T4 DNA Ligase 10x Buffer as 
well as 1.5 u T4 DNA Ligase and was filled up with water to a final volume of 20 µl. After an 
incubation of three hours at room temperature the inactivation of the enzyme occurred at 
65 °C for ten minutes. 
 
 
6.4.10 Amplification and preparation of plasmids 
 
6.4.10.1 Electro transformation 
For transformation of bacteria via electroporation electro competent Escherichia coli (strain 
DH10B) were thawed on ice. 40 µl of competent bacteria were incubated with 1 to 3 µl 
plasmid DNA for two minutes on ice. Afterwards the reaction mixture was transferred into an 
electroporation cuvette and treated with a short voltage surge of 1.8 kV. Immediately after 
the bacteria were mixed with 1 ml LB medium and incubated for one hour at 37 °C in a 
shaker. Subsequently, bacteria were spread on agar plates with selection medium according 
to the plasmid resistance which were incubated at 37 °C over night. 
 
6.4.10.2 Mini and Maxi Preparation 
The preparations of plasmids in a small scale were done with the QIAprep® SpinMiniprep Kit 
(Qiagen, Hilden, Germany, 27106) according to the instructions of the manufacturer. 
Large scale plasmid preparations were done with the Qiagen® Plasmid Maxi Kit (Qiagen, 
Hilden, Germany, 12163) according to the instructions of the manufacturer. 
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Table S2 Gene Ontology (GO) categories applied for genes set enrichment analyses. 
Divided into two parts (A + B). 
 
A. Gene ontology (GO) categories related to cholesterol and/ or lipid metabolism applied for gene set enrichment analyses 
 
 
 
No. GO ID GO-term Annotated Significant Expected P-value Bonferroni BH
1 GO:0006695 cholesterol biosynthetic process 39 13 0.43 1.5e-16 1.35E-12 1.35E-12
2 GO:0008610 lipid biosynthetic process 409 29 4.54 1.0e-15 9.00E-12 3.90E-12
3 GO:0016126 sterol biosynthetic process 45 13 0.5 1.3e-15 1.17E-11 3.90E-12
4 GO:0008203 cholesterol metabolic process 101 15 1.12 3.2e-13 2.88E-09 7.20E-10
5 GO:0016125 sterol metabolic process 108 15 1.2 8.8e-13 7.92E-09 1.58E-09
6 GO:0006629 lipid metabolic process 975 37 10.83 2.3e-11 2.07E-07 3.45E-08
7 GO:0006694 steroid biosynthetic process 124 14 1.38 9.2e-11 8.28E-07 1.18E-07
8 GO:0008202 steroid metabolic process 258 18 2.87 5.5e-10 4.95E-06 6.18E-07
9 GO:0006633 fatty acid biosynthetic process 111 11 1.23 4.1e-08 0.0004 4.10E-05
10 GO:0008299 isoprenoid biosynthetic process 20 6 0.22 5.8e-08 0.0005 4.65E-05
11 GO:0044255 cellular lipid metabolic process 657 25 7.3 6.2e-08 0.0006 4.65E-05
12 GO:0006631 fatty acid metabolic process 256 14 2.84 1.0e-06 0.0090 0.0006
13 GO:0035336 long-chain fatty-acyl-CoA metabolic process 18 5 0.2 1.2e-06 0.0108 0.0007
14 GO:0035338 long-chain fatty-acyl-CoA biosynthetic process 18 5 0.2 1.2e-06 0.0108 0.0007
15 GO:0035337 fatty-acyl-CoA metabolic process 19 5 0.21 1.6e-06 0.0144 0.0008
16 GO:0046949 fatty-acyl-CoA biosynthetic process 19 5 0.21 1.6e-06 0.0144 0.0008
17 GO:0035384 thioester biosynthetic process 20 5 0.22 2.1e-06 0.0189 0.0009
18 GO:0071616 acyl-CoA biosynthetic process 20 5 0.22 2.1e-06 0.0189 0.0009
19 GO:0019432 triglyceride biosynthetic process 37 6 0.41 3.0e-06 0.0270 0.0012
20 GO:0046460 neutral lipid biosynthetic process 39 6 0.43 4.1e-06 0.0369 0.0015
21 GO:0046463 acylglycerol biosynthetic process 39 6 0.43 4.1e-06 0.0369 0.0015
22 GO:0046504 glycerol ether biosynthetic process 44 6 0.49 8.5e-06 0.0765 0.0031
23 GO:0016053 organic acid biosynthetic process 205 11 2.28 1.8e-05 0.1619 0.0060
24 GO:0046394 carboxylic acid biosynthetic process 205 11 2.28 1.8e-05 0.1619 0.0060
25 GO:0006637 acyl-CoA metabolic process 33 5 0.37 2.9e-05 0.2609 0.0087
26 GO:0035383 thioester metabolic process 33 5 0.37 2.9e-05 0.2609 0.0087
27 GO:0006641 triglyceride metabolic process 80 7 0.89 2.9e-05 0.2609 0.0087
28 GO:0033559 unsaturated fatty acid metabolic process 58 6 0.64 4.3e-05 0.3868 0.0121
29 GO:0006639 acylglycerol metabolic process 86 7 0.96 4.7e-05 0.4228 0.0122
30 GO:0006720 isoprenoid metabolic process 59 6 0.66 4.7e-05 0.4228 0.0122
31 GO:0032787 monocarboxylic acid metabolic process 408 15 4.53 4.9e-05 0.4408 0.0122
32 GO:0006638 neutral lipid metabolic process 87 7 0.97 5.1e-05 0.4587 0.0124
33 GO:0048008
platelet-derived growth factor receptor 
signaling pathway 22 4 0.24 9.2e-05 0.8275 0.0218
34 GO:0006636 unsaturated fatty acid biosynthetic process 42 5 0.47 9.7e-05 0.8725 0.0218
35 GO:0044281 small molecule metabolic process 1846 38 20.5 9.7e-05 0.8725 0.0218
36 GO:0006662 glycerol ether metabolic process 100 7 1.11 0.0001 1 0.0263
37 GO:0006693 prostaglandin metabolic process 24 4 0.27 0.0001 1 0.0278
38 GO:0018904 organic ether metabolic process 102 7 1.13 0.0001 1 0.0293
39 GO:0045017 glycerolipid biosynthetic process 111 7 1.23 0.0002 1 0.0459
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B. GO categories unrelated to cholesterol and/ or lipid metabolism used as reference for gene set enrichment analyses 
 
 
 
Table S3 Bartz et al. RNAi-screening results for C17orf59 
Overview of the RNAi screening results from Bartz et al. for six different siRNAs against C17orf59 and 
their influence on (A) DiI-LDL uptake (B) Filipin (lysosomal signal) and (C) Tf-568 uptake compared to 
control (*p < 0.05; ***p < 0.001). 
 
 
No. GO ID GO-term Annotated Significant Expected P-value Bonferroni BH
1 GO:0051726 regulation of cell cycle 559 23 6.21 5.5e-08 0.0005 4.65E-05
2 GO:0007049 cell cycle 1146 33 12.73 2.9e-07 0.0026 0.0002
3 GO:0006066 alcohol metabolic process 493 19 5.48 2.3e-06 0.0207 0.0010
4 GO:0008283 cell proliferation 1185 29 13.16 4.0e-05 0.3598 0.0116
5 GO:0022402 cell cycle process 835 23 9.27 4.8e-05 0.4318 0.0122
6 GO:0000279 M phase 454 15 5.04 0.0002 1 0.0327
7 GO:0048523 negative regulation of cellular process 1979 39 21.98 0.0002 1 0.0400
8 GO:0051301 cell division 363 13 4.03 0.0002 1 0.0411
9 GO:0048519 negative regulation of biological process 2147 41 23.85 0.0003 1 0.0468
10 GO:0000087 M phase of mitotic cell cycle 328 12 3.64 0.0003 1 0.0551
A. DiI-LDL uptake
siRNA ID name (this work) n (exp) mean STDEV SEM DEV p
43607 si C17orf59-3 10 0.82 0.08 0.03 3.19 ***
43680 si C17orf59-1 10 0.67 0.19 0.06 2.58 ***
140408 not us ed 6 0.87 0.19 0.08 0.85
SI00396480 not us ed 4 1.11 0.27 0.15 -0.43
SI00396487 not us ed 7 0.73 0.35 0.14 0.86
SI03194457 si C17orf59-2 8 0.75 0.27 0.10 1.13 *
B. Filipin (lysosomal signal)
siRNA ID name (this work) n (exp) mean STDEV SEM DEV p
43607 si C17orf59-3 5 1.13 0.19 0.09 -0.54
43680 si C17orf59-1 6 0.95 0.21 0.10 0.42
140408 not us ed 4 1.03 0.38 0.22 -0.01
SI00396480 not us ed 9 1.05 0.29 0.10 -0.23
SI00396487 not us ed 10 0.94 0.15 0.05 0.63
SI03194457 si C17orf59-2 10 1.16 0.39 0.13 -0.59
C. Tf-568 uptake
siRNA ID name (this work) n (exp) mean STDEV SEM DEV p
43607 si C17orf59-3 8 1.27 0.32 0.12 -1.11
43680 si C17orf59-1 8 0.92 0.13 0.05 0.86
140408 not us ed 8 1.12 0.38 0.14 -0.43
SI00396480 not us ed 14 0.96 0.91 0.25 -0.05
SI00396487 not us ed 17 1.00 0.78 0.20 -0.16
SI03194457 si C17orf59-2 11 1.40 0.58 0.18 -1.26 *
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Figure S1 Conservation of the protein C17orf59 in mammals. (A) Human locus of C17orf59 from UCSC 
genome browser (Raney et al., 2011) with 46-way multiZ nucleotide alignments (Blanchette et al., 
2004) to illustrate conservation of sequences across vertebrate genomes (http://genome.ucsc.edu/). 
(B) Alignment of human C17orf59 protein to selected eutherian mammal species. (prepared by 
Michael Eichenlaub) 
 
 
 
 
 
 
 
 
 
 
  SUPPLEMENT 
 
 
111 
 
Figure S2 Vector card of pOTB7. This vector, including C17orf59-T2 (BC0188880) between restriction 
sites of EcoRI and XhoI, was bought from imaGenes (clone ID IRAUp969C1150D) and was used as 
source for the C17orf59-T2 sequence, which was then cloned into pEGFP-N2 (see Figure S3). 
 
 
Figure S3 Vector card of pEGFP-N2. This vector (GeneBank Accession #: U57608) was used to clone 
the plasmids pEGFP-N2-C17orf59-T1 and pEGFP-N2-C17orf59-T2. C17orf59 was cloned into the 
multiple cloning site (MCS) using the restriction enzymes BglII and SalI (Table 6.6). This vector builds 
also the backbone of the mutated C17orf59 constructs pEGFP-N2-C17orf59-T2_C555T and pEGFP-N2-
C17orf59-T1_C957T (Table 6.5) used for rescue experiments (3.2.5). 
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Figure S4 Vector card of pET-28M-SUMO1-GFP. This vector was provided by the Protein Expression & 
Purification Core Facility at EMBL Heidelberg. It was used to create C17orf59 constructs for bacterial 
expression in order to purify C17orf59 protein, which was then used for the production of a C17orf59 
polyclonal rabbit antibody (6.3.8). For this, the EGFP sequence was cut off and replaced by C17orf59 
(BC0188880).Cloning was done by Susanne Theiß. 
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